10 Things to Know About Medicaid Managed Care

Published: Mar 23, 2026

Key Facts

Introduction

Managed care is the dominant delivery system for people enrolled in Medicaid. The latest national Medicaid managed care enrollment data (from 2024) show 78% of Medicaid beneficiaries were enrolled in comprehensive managed care organizations (MCOs). While managed care is the dominant Medicaid delivery system, states decide which populations and services to include in managed care arrangements, which leads to considerable variation across states. Additionally, while state requirements for Medicaid managed care plans can be tracked, plans have flexibility in certain areas, including in setting provider payment rates, and plans may choose to offer additional benefits beyond those required by the state.

States and plans faced considerable rate setting uncertainty after millions of people were disenrolled during the “unwinding” of the pandemic-era Medicaid continuous enrollment provision. Many states sought federal approval to adjust rates to address shifts in utilization and acuity—as people who used fewer services than average were disenrolled, leaving a group with higher health risk and spending. Looking ahead, states expect the 2025 federal budget reconciliation law will create additional managed care plan rate setting challenges as the Medicaid provisions impacting enrollment and spending (e.g., program financing changes, work requirements, and more frequent eligibility redeterminations) roll out over the next several years. Federal Medicaid spending cuts, coupled with a more tenuous fiscal climate (at the state-level), will have implications for states and enrollees as well as plans and providers. In this context, this brief describes 10 themes related to the use of comprehensive, risk-based managed care in the Medicaid program.

1. Capitated managed care is the dominant way in which states deliver services to Medicaid enrollees.

States design and administer their own Medicaid programs within federal rules. States determine how they will deliver and pay for care for Medicaid beneficiaries. Nearly all states have some form of managed care in place – comprehensive risk-based managed care (i.e., contracts with MCOs) and/or primary care case management (PCCM) programs.1, 2 As of July 2025, 42 states (including DC) contract with comprehensive, risk-based managed care plans to provide care to at least some of their Medicaid beneficiaries (Figure 1). Oklahoma is the latest state to be included in this count, having implemented capitated, comprehensive Medicaid managed care (for most children and adults) on April 1, 2024. Following the passage of state legislation, Idaho ended its PCCM program effective January 1, 2026 and expects to implement comprehensive MCOs in January 2030. Medicaid MCOs provide comprehensive acute care (i.e., most physician and hospital services) and, in some cases, long-term care to Medicaid beneficiaries and are paid a set per member per month payment for these services. For more than three decades, states have increased their reliance on managed care delivery systems with the aim of improving access to certain services, enhancing care coordination and management, and making future costs more predictable. While the shift to MCOs has increased budget predictability for states, the evidence about the impact of managed care on access to care and costs is both limited and mixed.3,4,5

As of July 2025, 42 States Contract with Comprehensive, Risk-based Managed Care Plans to Deliver Services in Medicaid (Choropleth map)

2. In FY 2024, payments to comprehensive risk-based MCOs accounted for half of Medicaid spending.

In FY 2024, state and federal spending on Medicaid services totaled $919 billion. Payments made to MCOs accounted for about 50% of total Medicaid spending (Figure 2). The share of Medicaid spending on MCOs varies by state, but about three-quarters of MCO states directed at least 40% of total Medicaid dollars to payments to MCOs (Figure 3). State-to-state variation reflects many factors, including the proportion of the state Medicaid population enrolled in MCOs, the health profile of the Medicaid population, whether high-risk/high-cost beneficiaries (e.g., people with disabilities, dual-eligible beneficiaries) are included in or excluded from MCO enrollment, and whether long-term care services are included in MCO contracts. As states continue to expand Medicaid managed care to include higher-need, higher-cost beneficiaries, expensive long-term care, and adults eligible for Medicaid under the Affordable Care Act (ACA), the share of Medicaid dollars going to MCOs could continue to increase.

Payments to Comprehensive MCOs Account for Half of Total National Medicaid Spending (Pie Chart)
In Most MCO States, Spending on MCOs Makes Up at Least 40% of Total Medicaid Spending (Choropleth map)

3. Over three-quarters (78%) of all Medicaid beneficiaries received their care through comprehensive risk-based MCOs.

As of July 1, 2024, over 66 million Medicaid enrollees, or 78% of all Medicaid enrollees, received their care through risk-based MCOs. Thirty MCO states covered at least 75% of Medicaid beneficiaries in MCOs (Figure 4).

In Most States With Comprehensive MCOs, at Least 75% of Beneficiaries Are Enrolled in One (Choropleth map)

4. Children and adults are groups most likely to be enrolled in MCOs.

Among states that contract with comprehensive Medicaid MCOs, children and ACA expansion adults are the most likely to be enrolled in comprehensive MCOs (90% and 86%, respectively) (Figure 5). Nearly three quarters (72%) of “other adults” (e.g., parents and pregnant individuals) were enrolled in comprehensive MCOs (in 2023). People eligible for Medicaid through a disability pathway and adults ages 65+ are less likely to be enrolled in comprehensive MCOs, although states have been moving to include these groups in MCOs over time.

Among States with Comprehensive MCOs, Children and ACA Expansion Adults Have Highest Rates of Enrollment in Comprehensive MCOs (Bar Chart)

5. Five publicly traded firms account for almost half of MCO enrollment.

States contracted with a total of 291 Medicaid MCOs as of July 2024. MCOs represent a mix of private for-profit, private non-profit, and government plans. As of July 2024, a total of 15 firms operated Medicaid MCOs in two or more states (called “parent” firms), and these firms accounted for over 62% of enrollment in 2024 (Figure 6). Of the 15 parent firms, six are publicly traded, for-profit firms while the remaining nine are non-profit companies. Five firms – Centene, UnitedHealth Group, Elevance (formerly Anthem), Molina, and Aetna/CVS – account for 47% of all Medicaid MCO enrollment (Figure 6). All five are publicly traded companies ranked in the Fortune 500, and four are ranked in the top 100.

Five Fortune 500 Companies Have Almost Half of the Medicaid MCO Market (Donut Chart)

6. States make decisions about which services to carve in and out of MCO contracts. 

Although MCOs provide comprehensive services to beneficiaries, states may carve specific services out of MCO contracts to fee-for-service systems or limited benefit plans. Services frequently carved out include dental, non-emergency medical transportation (NEMT), and behavioral health. Among those enrolled in comprehensive MCOs, over two-thirds were also enrolled in at least one limited benefit prepaid health plan (PHP) and/or received fee-for-service (FFS) care outside of their MCO in 2023 (Figure 7).  People with disabilities (enrolled in an MCO) are most likely to also be enrolled in a limited benefit plan(s) and/or receive FFS care. Individuals enrolled in multiple plans (i.e., MCO + limited benefit PHP(s)) or delivery systems (i.e., MCO + FFS) may have to juggle multiple complex systems, with differing rules. Among MCO enrollees also enrolled in at least one limited benefit plan, over half were enrolled in a dental plan (Figure 8). (Note that while EPSDT requires states to provide comprehensive dental services for children, dental benefits are optional for adults. State Medicaid programs are required to provide necessary transportation for enrollees to and from providers (referred to as “non-emergency medical transportation” or “NEMT”).)

Among Enrollees in Comprehensive MCOs, Over Two-Thirds Were Also Enrolled in a Limited Benefit Plan and/or Received Services Through FFS (Stacked column chart)
Over Half of Enrollees in a Comprehensive MCO and Any Limited Benefit Plan Were Enrolled in a Dental Plan (Split Bars)

7. Each year, states develop MCO capitation rates that must be actuarially sound and may include risk mitigation strategies.

MCOs are at financial risk for services covered under their contracts, receiving a per member per month “capitation” payment for these services. While plans set rates in the commercial and Medicare Advantage markets, Medicaid managed care rates are developed by states and their actuaries and reviewed and approved by CMS. Capitation rates must be actuarially sound6 and are applied prospectively, typically for a 12-month rating period, regardless of changes in health care costs or utilization. States may use a variety of risk mitigation tools to ensure payments are not too high or too low, including risk sharing arrangements, risk and acuity adjustments, or medical loss ratios (MLR) remittance requirements. States may also incorporate quality metrics into the ongoing monitoring of their programs, including linking financial incentives (e.g., performance bonuses or withholds) to quality measures.

To limit the amount that plans can spend on administration and keep as profit, states are required to develop capitation rates for Medicaid to achieve an MLR of at least 85% in the rate year;7 however, there is no federal requirement for Medicaid plans to pay remittances to the state if they fail to meet the MLR standard.8 As of July 2025, 33 MCO states reported they always require remittance payments when an MCO does not meet state minimum MLR requirements, while three states indicated they sometimes require MCOs to pay remittances (Figure 9). Analysis of National Association of Insurance Commissioners (NAIC) data for the Medicaid managed care market show that average loss ratios (in aggregate across plans) increased from 88% in 2023 to 91% in 2024 (Figure 10) (the highest Medicaid managed care average loss ratio observed in the past decade – data not fully shown).

When significant enrollment, utilization, cost, and acuity changes began to emerge early in the COVID-19 public health emergency, CMS allowed states to modify managed care contracts, and many states implemented COVID-19 related “risk corridors” (where states and health plans agree to share profit or losses), allowing for the recoupment of funds. States and plans faced another period of heightened rate setting uncertainty when the continuous enrollment provision expired on March 31, 2023. During the “unwinding” of the pandemic-era Medicaid continuous enrollment provision, millions of people were disenrolled. Higher member risk and utilization patterns began to emerge by late 2023, and many states sought federal approval to adjust rates to address these shifts. The 2025 federal budget reconciliation law is expected to create rate setting challenges for states as the Medicaid provisions impacting enrollment and spending (e.g., work requirements, more frequent eligibility redeterminations, and provider tax and state directed payment (SDP) caps and reductions) roll out over the next several years.

Most MCO States Always Require Remittance Payments When an MCO Does Not Meet Minimum Medical Loss Ratio (MLR) Requirements (Choropleth map)
The Average Medical Loss Ratio for the Medicaid Managed Care Market Increased from 88% in 2023 to 91% in 2024 (Column Chart)

8. Changes to federal state directed payment rules may impact provider payments.

States are generally prohibited from contractually directing how a managed care plan pays its providers.9 Subject to CMS approval, however, states may implement certain “state directed payments” (SDPs) that require managed care plans to adopt minimum or maximum provider payment fee schedules, provide uniform dollar or percentage increases to providers (above base payment rates), or implement value-based payment (VBP) arrangements.10,11,12 Many states that contract with MCOs use SDPs to make uniform rate increases that are like FFS supplemental payments. Since SDPs were introduced in 2016, they have become a core component of reimbursement for many providers. Significant changes to state directed payment rules recently enacted through the 2025 federal budget reconciliation law and through the 2024 CMS Managed Care rule are expected to affect Medicaid provider payment rates.

The reconciliation law directs HHS to revise SDP regulations to cap the total payment rate for inpatient and outpatient hospital services, nursing facility services, and professional services at academic medical centers at 100% of the total published Medicare payment rate for states that have adopted the Medicaid expansion and at 110%13 of the total published Medicare payment rate for states that have not adopted the expansion. (Under previous rules, payments were capped at 100% of average commercial rates.14) Certain SDPs are initially grandfathered15 but will be reduced by ten percentage points each year (starting January 1, 2028) until they reach the allowable Medicare-related payment limit. The Congressional Budget Office (CBO) estimated revising the payment limit for state directed payments will result in $149 billion in federal savings over ten years (Figure 11). The 2025 reconciliation law also imposes significant new restrictions on states’ ability to generate Medicaid provider tax revenue, estimated to result in $226 billion in federal savings (Figure 11). In KFF’s 2025 Medicaid budget survey, states noted the new provider tax changes could result in significant state budget impacts as well as reductions in provider payment rates and state directed payments, which are often funded by provider taxes.

The 2025 Reconciliation Law Imposes Restrictions on Medicaid Financing and State Directed Payments That Could Have Implications for MCOs and Providers (Donut Chart)

In addition to the 2025 reconciliation law changes, beginning in July 2027, the 2024 Medicaid Managed Care rule requires states to incorporate all SDPs through capitation rate setting adjustments instead of using “separate payment terms,” which provide payments outside of base capitation rates.16 The change moves these payments from predictable, separate payments to more complex, risk-based arrangements, which may reduce states’ ability to target reimbursement for specific provider types. CMS eliminated separate payment terms due to concerns that these separate payments undermine the risk-based nature of managed care and are frequently driven by the financing of the non-federal share. MACPAC analysis found that over half of SDP arrangements approved between February 2023 and August 2024 were incorporated through separate payment terms.

9. CMS finalized rules to strengthen access standards, but the future of the rules is uncertain.  

In 2024, the Biden administration finalized major Medicaid regulations designed to promote quality of care and advance access to care for Medicaid enrollees. The Managed Care rule strengthens standards for timely access to care, including through the establishment of national maximum wait time standards for certain “routine” appointments, and states’ monitoring and enforcement efforts. These rules are complex and set to be implemented over several years. It remains uncertain whether the Trump administration will seek to roll back or revise provisions included in the 2024 managed care final rules. 

In 2024, CMS also finalized a rule focused on improving the prior authorization process including reducing approval wait times and improving transparency. A July 2023 OIG report found that Medicaid MCOs had an overall prior authorization denial rate of 12.5%–more than 2 times higher than the Medicare Advantage rate (Figure 12), raising concerns about prior authorization and access in Medicaid managed care. OIG recommendations (to CMS) included strengthening state monitoring of denials and appeals. MACPAC has highlighted similar concerns, making recommendations in the March 2024 Report to Congress focused on improving the appeals process and enhancing monitoring and oversight of MCOs. Beginning in June 2026, states will be required to report plan-level prior authorization data to CMS, including the total number prior authorization requests, denial and approval rates, the percentage of standard prior authorization requests that were approved after appeal, and average and median decision times as part of managed care annual program reports (see additional discussion below). 

Medicaid MCOs Have an Overall Prior Authorization Denial Rate More Than 2 Times Higher Than the Medicare Advantage Rate (Grouped column chart)

While health insurers are increasingly using AI to automate parts of the prior authorization process, there is limited information available about its use and impact within Medicaid managed care. MACPAC found that while there are potential benefits of automation in prior authorization such as administrative efficiencies and faster processing times, it may also pose potential risks or challenges depending on how it is administered and monitored. In the absence of comprehensive federal policy governing AI use and oversight in prior authorization, some states have taken steps to regulate or monitor use of AI by health plans. A 2025 KFF survey of state Medicaid directors found less than one-quarter of states reported requiring MCOs to disclose the use of AI in prior authorization processes as of July 1, 2025, although nearly half of MCO states reported knowledge of at least some of their contracted MCOs using AI in their prior authorization processes (Figure 13). Several states reported implementing new or expanded oversight activities or adopting other safeguards in FY 2025 or 2026 to support appropriate use of AI in MCO prior authorization processes.

Nearly Half of MCO States Reported MCO Use of AI in their Prior Authorization Processes as of July 1, 2025 (Choropleth map)

10. In recent years, CMS has taken steps to improve managed care program monitoring and transparency.

The 2016 Medicaid managed care final rule created new managed care reporting requirements for states. CMS, under the Biden administration, developed standard reporting templates (Table 1) and a variety of toolkits and released a series of informational bulletins (2021, 2022, 2023, 2024) to help states improve their monitoring and oversight of managed care programs. Transparency has the potential to promote accountability. To improve transparency, CMS began publicly posting the Managed Care Program Annual Report (MCPAR) and the MLR Summary Reports on Medicaid.gov in 2024. Posting data relating to the performance of individual MCOs may allow for comparison within and across states. However, limitations and challenges may exist.

Managed care rules finalized in 2024 include provisions aimed at further strengthening managed care transparency and monitoring, though the fate of these rules remains uncertain. In March 2026,  the Trump administration released an informational bulletin to aid states’ monitoring and oversight of managed care. CMS indicated it has implemented managed care oversight reviews that will leverage data collected from standardized reporting tools (e.g., MCPARs, network adequacy and access reports, and MLR summary reports). While CMS has continued to post state-submitted MCPAR and MLR summary reports on Medicaid.gov, it has also updated MCPAR requirements to remove certain questions related to access and network adequacy and plan-level MLR percentage reporting. These changes were introduced to reduce state burden and duplication with the separate network adequacy and access report and the MLR summary report; however, removing certain access and network adequacy questions may also reduce transparency as state network adequacy and access reports are not currently posted on Medicaid.gov. While the MLR Summary Reports are posted on Medicaid.gov, in the future, individuals will need to access the MLR Summary Reports separately to obtain plan-level MLR reporting information (as it will no longer be available in MCPAR reports). 

To Improve Transparency, CMS Began Publicly Posting Some State Managed Care Reports in 2024 (Table)

This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Methods

Medicaid Managed Care Plan Enrollment by Eligibility Group

This section provides information on the methods used in the analysis of Medicaid managed care plan enrollment by eligibility group (Figures 5, 7, and 8).

Data: This analysis uses data available from the 2023 T-MSIS Research Identifiable Demographic-Eligibility and Claims Files to identify enrollment in Medicaid managed care plans.

Medicaid enrollee inclusion criteria: Individuals were included if they had at least one month of Medicaid enrollment in 2023.  This analysis identified Medicaid enrollment in a month (MM) in 2023 when CHIP_CD_01- CHIP_CD_12 equals 1 or, if missing CHIP_CD, when ELGBLTY_GRP_CD_01- ELGBLTY_GRP_CD_12 equals 1-60 or 69-75. Eligibility groups are defined using the most recent non-missing eligibility group in the calendar year (ELGBLTY_GRP_CD_LTST) and a person’s age as follows:

  • Seniors: Enrollees age 65 and older.
  • People with Disabilities: Enrollees under age 65 who are reported as eligible because of disability.
  • Adults: Enrollees ages 19 to 64 who are not eligible because of disability or newly eligible for Medicaid by the ACA Medicaid expansion.
  • Children: Enrollees ages 18 and younger who are not eligible because of disability.
  • ACA Expansion Adults: Enrollees ages 19 to 64 who were made newly eligible for Medicaid by the ACA Medicaid expansion.

State inclusion criteria: To assess the usability of states’ data, the analysis examined quality assessments from the DQ Atlas for enrollment in managed care and payments to comprehensive managed care plans and compared enrollment in comprehensive managed care with the Medicaid Managed care enrollment report:

  • This analysis excluded 10 states with no comprehensive Medicaid managed care plans in 2023 (Alabama, Alaska, Connecticut, Idaho, Maine, Montana, Oklahoma, South Dakota, Vermont, and Wyoming).
  • Among states with Medicaid managed care, the analysis excluded states that had both a “Unclassified/ Unusable” DQ Atlas assessment and more than 50% difference between the number of individuals enrolled in managed care in T-MSIS and the number reported in the Medicaid managed care enrollment report.
  • No states were excluded based on those criteria in 2023, leaving the other 40 states and D.C. (hereafter, treated as a state) which contract with comprehensive MCOs in the main analysis. Enrollees were assigned a state based on their T-MSIS STATE_CD.

Identifying enrollment in Medicaid managed care plans: To determine enrollment in plans in 2023, individuals were assigned as enrolled in any plans from the list MC_PLAN_ID_01_MMMC_PLAN_ID_16_MM from the Managed Care Participation segment of the T-MSIS eligibility file. To determine enrollment in comprehensive MCOs, enrollment was limited to plans from the list MC_PLAN_ID_01_MMMC_PLAN_ID_16_MM from the Managed Care Participation segment of the T-MSIS eligibility file which also have a positive capitated payment to a plan on behalf of the enrollee in the month (MM) in the T-MSIS Other Services (OT) file. This analysis calculated positive capitated payment to a plan on behalf of the enrollee in a month by summing the MDCD_PD_AMT for claims with CLM_TYPE_CD equal to ”2” (Medicaid or Medicaid-expansion Capitated Payment) having a SRVC_END_DT in the month in 2023. Capitated payments were attributed to a specific plan using the MC_PLAN_ID from the OT file.

Identifying Medicaid managed care plan types: This analysis used the Managed Care Participation segment of the T-MSIS eligibility file to map each plan as identified by its MC_PLAN_ID and STATE_CD to its plan type using the associated MC_PLAN_TYPE_CD. In cases where the plan as identified by MC_PLAN_ID and STATE_CD had more than one associated MC_PLAN_TYPE_CD in the Managed Care Participation segment of the T-MSIS eligibility file, the MC_PLAN_TYPE_CD with the largest number of enrollees in that plan was selected. This virtually always matches the MC_PLAN_TYPE_CD from the TAF Annual Managed Care Plan (APL).

KFF created indicator variables to assign the more detailed plan types into the following larger categories. Note that plan types are not mutually exclusive. For example, while there are no plans in 2023 have a MC_PLAN_TYPE_CD of 19 (Individual is enrolled in Long-Term Services and Supports (LTSS) and Mental Health (MH) PIHP), plans of this plan type would fall under both behavioral health and long-term care. KFF grouped the more detailed plan types into the following larger categories:

  • Comprehensive managed care: having a MC_PLAN_TYPE_CD with values of 01 (Comprehensive managed care) or 04 (Health Insuring Organization).
  • Program of All-Inclusive Care for the Elderly (PACE): having a MC_PLAN_TYPE_CD with values of 17 (PACE).
  • Long-term care: having a MC_PLAN_TYPE_CD with values of 07 (Long Term Care Services and Supports (LTSS) PIHP) or 19 (Individual is enrolled in Long-Term Services and Supports (LTSS) and Mental Health (MH) PIHP).
  • Behavioral health: having a MC_PLAN_TYPE_CD with values of 08 (Mental Health (MH) PIHP), 09 (Mental Health (MH) PAHP), 10 (Substance Use Disorders (SUD) PIHP), 11 (Substance Use Disorders (SUD) PAHP), 12 (Mental Health (MH) and Substance Use Disorders (SUD) PIHP), 13 (Mental Health (MH) and Substance Use Disorders (SUD) PAHP), or 19 (Individual is enrolled in Long-Term Services and Supports (LTSS) and Mental Health (MH) PIHP).
  • Dental: having a MC_PLAN_TYPE_CD with values of 14 (Dental PAHP).
  • Transportation: having a MC_PLAN_TYPE_CD with values of 15 (Transportation PAHP).
  • Other limited benefit: having a MC_PLAN_TYPE_CD with values of 05 (Medical-only Prepaid Inpatient Health Plan (PIHP)), 06 (Medical-only Prepaid Ambulatory Health Plan (PAHP)), 16 (Disease Management PAHP), 18 (Pharmacy PAHP), or 20 (Other).
  • Any limited benefit: having a MC_PLAN_TYPE_CD with values defined above as long-term care, behavioral health, dental, transportation, or other limited benefit.
  • Primary care case management (PCCM): having a MC_PLAN_TYPE_CD with values of 02 (Traditional Primary Care Case Management (PCCM) Provider arrangement), or 03 (Enhanced PCCM Provider arrangement).

Managed long-term care (LTC) limited benefit plans: Using the definitions above, in 2023, virtually zero enrollees in long-term care limited benefit plans were concurrently enrolled in a comprehensive MCO. The likely reason there are no enrollees in comprehensive MCOs and limited benefit LTC plans is that most enrollees in limited benefit LTC plans also have Medicare. For such people (“dual-eligible individuals”), Medicaid covers medical acute and post-acute care, including skilled nursing facility services and home health care. Medicaid wraps around Medicare coverage by paying Medicare premiums and in most cases, cost sharing. Most people with Medicare and Medicaid (“dual-eligible individuals”) also are eligible for Medicaid benefits that are not otherwise covered by Medicare, including long-term carevision, and dental. It is unlikely that many dual-eligible individuals who are enrolled in LTC plans would also use many benefits provided through a comprehensive MCO.

Endnotes

  1. PCCM is a managed fee-for-service (FFS) based system in which beneficiaries are enrolled with a primary care provider who is paid a small monthly fee to provide case management services in addition to primary care. ↩︎
  2. While MCOs are the predominant form of Medicaid managed care, millions of other beneficiaries receive at least some Medicaid services, such as behavioral health or dental care, through limited-benefit risk-based plans, known as prepaid inpatient health plans (PIHPs) and prepaid ambulatory health plans (PAHPs). ↩︎
  3. Sparer M. 2012. Medicaid managed care: costs, access, and quality of care. Res. Synth. Rep. 23, Robert Wood Johnson Found., Princeton, NJ ↩︎
  4. Daniel Franco Montoya, Puneet Kaur Chehal, and E. Kathleen Adams, “Medicaid Managed Care’s Effects on Costs, Access, and Quality: An Update,” Annual Review of Public Health 41:1 (2020):537-549 ↩︎
  5. Medicaid and CHIP Payment and Access Commission (MACPAC), “Managed care’s effect on outcomes,” (Washington, DC: MACPAC, 2018), https://www.macpac.gov/subtopic/managed-cares-effect-on-outcomes/ ↩︎
  6. Federal regulations require actuarially sound capitation rates that are “projected to provide for all reasonable, appropriate, and attainable costs that are required under the terms of the contract and for the operation of the MCO, PIHP, or PAHP for the time period and the population covered under the terms of the contract . . .” 42 CFR §438.4(a) ↩︎
  7. The 85% minimum MLR is the same standard that applies to Medicare Advantage and private large group plans. ↩︎
  8. The 2024 Consolidated Appropriations Act included a financial incentive to encourage certain states to collect remittances from Medicaid MCOs that do not meet minimum MLR requirements. ↩︎
  9. 42 CFR Sections 438.6(c) and 438.60. ↩︎
  10. Permissible under 42 CFR Section 438.6(c). ↩︎
  11. In creating state directed payments (in 2016), CMS aimed to help states ensure access to adequate provider networks and to increase use of VBP arrangements. ↩︎
  12. State directed payments must meet federal requirements (e.g., must be tied to utilization and delivery of services, be distributed equally to specified providers, and not be conditioned on participation in intergovernmental transfer (IGT) agreements) (42 CFR §438.6(c)). ↩︎
  13. For states that newly adopt the ACA Medicaid expansion after enactment, the cap at 100% of the Medicare payment rate applies at the time coverage is implemented even for SDPs that had prior approval. ↩︎
  14. The managed care rules finalized in 2024 permitted states to pay hospitals and nursing facilities at the average commercial payment rate (ACR) when using directed payments, (higher than the Medicare payment ceiling used for other Medicaid FFS supplemental payments). ↩︎
  15. Specifies that the grandfathering clause only applies to SDPs in rating periods occurring 180 business days before or after enactment of the bill (July 4, 2025) and that (1) for rural hospitals, states received approval or made a “good faith effort” to receive approval prior to enactment of the bill; (2) for all other providers, states received approval or made a “good faith effort” to receive approval prior to May 1, 2025; or (3) states applied for approval prior to enactment of the bill. ↩︎
  16. “Separate payment terms are a type of payment method that provides a fixed amount of directed payment funding outside of the base capitation rate. States often use separate payment terms to make large uniform rate increases…Under the 2024 managed care rule, separate payment terms will be eliminated effective for the first rating period beginning on or after July 9, 2027, and all directed payment arrangements will henceforth be required to be incorporated through capitation rate adjustments. CMS eliminated separate payment terms due to concerns that payment streams separate from capitation rates undermine the risk-based nature of managed care and are often driven by the underlying financing of the non-federal share.” Medicaid and CHIP Payment And Access Commission, “Directed Payments in Medicaid Managed Care,” October 2024 Issue Brief, p.6, https://www.macpac.gov/wp-content/uploads/2024/10/Directed-Payments-in-Medicaid-Managed-Care.pdf. ↩︎

The President’s Malaria Initiative and Other U.S. Government Global Malaria Efforts

Published: Mar 23, 2026

Editorial Note: Originally published in June 2009, this resource is updated as needed to reflect the latest developments.

Key Facts

  • About half of the world’s population is at risk of being infected with malaria. In 2024, there were an estimated 282 million cases of malaria and 610,000 deaths from malaria worldwide. Sub-Saharan Africa is the hardest hit region in the world.
  • While gains have been made over the past two decades in increasing access to malaria prevention and treatment, many challenges (including drug and insecticide resistance and climate change impacts) continue to complicate malaria control efforts in hard-hit areas. In promising developments in recent years, new tools against malaria, including dual-ingredient insecticide-treated nets and the world’s first malaria vaccines, are being integrated into broader health systems.
  • The U.S. government (U.S.) has been involved in global malaria activities since the 1950s and, today, is the largest donor government to global malaria efforts.
  • Historically, U.S. malaria efforts included activities primarily through the U.S. President’s Malaria Initiative (PMI), which was overseen by the U.S. Global Malaria Coordinator, as well as through other U.S. activities, collectively reaching approximately 30 countries.
  • U.S. funding for malaria control efforts and research activities was approximately $1 billion in FY 2026, up slightly from $963 million in FY 2017. Additionally, the U.S. is the largest donor to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), which in turn is the largest overall funder of malaria efforts in the world.
  • Since the beginning of the second Trump administration, the U.S. global health response has undergone a significant change (including a reorganization of foreign assistance, reductions in funding, and cancellation of programs), fundamentally altering the global health landscape as well as PMI and other U.S. global malaria efforts.

Global Situation1

Malaria is one of the world’s most common and serious tropical diseases, with about half the world’s population at risk of being infected with malaria. Although preventable and treatable, malaria causes significant morbidity and mortality, with the greatest numbers of cases and deaths in resource-poor regions and among young children.2

Malaria: an infectious disease caused by certain Plasmodium parasites, which are transmitted to humans by Anopheles mosquitoes. This mosquito thrives in warm, tropical, and subtropical climates. Infection with malaria parasites can cause common symptoms like fever, chills, and flu-like illness and lead to anemia, causing severe malaria disease and sometimes death. When the infected parasites clog small blood vessels in the brain, causing cerebral malaria, it can also be fatal.3

Strategies and efforts to address malaria have evolved over time, with global eradication efforts waning in the 1970s, resulting in rising rates.4 In the late 1990s, malaria began to receive renewed attention, particularly after the 1998 creation of the Roll Back Malaria Partnership (RBM), now referred to as the RBM Partnership to End Malaria.5 In 2000, all nations agreed to global malaria targets as part of Millennium Development Goal 6 (combat HIV/AIDS, malaria, and other diseases). Since then, expanded efforts by the U.S. government, other donor governments, multilateral institutions, and affected countries have helped to increase access to malaria prevention and treatment and reduce cases and deaths, and there has been, at times, discussion of the possibility of finally eradicating the disease.6

Today global malaria activities are focused on sustaining, improving, and expanding efforts to control the disease. Still, the rate of progress has stalled in some countries recently, and many challenges continue to complicate malaria control efforts in countries with ongoing malaria transmission, including poverty, poor sanitation, weak health systems, limited disease surveillance capabilities, natural disasters, armed conflict, migration, climate change, and the presence of counterfeit and/or sub-standard antimalarial drugs.7

Morbidity and Mortality8

  • WHO estimates that there were approximately 282 million cases of malaria and 610,000 deaths, mostly among children under the age of five, in 2024. Overall, substantial scale-up of malaria interventions helped reduce the malaria case incidence and death rates over the past two decades, though case incident rates were slightly higher in 2024 than in 2023 due to increased rates in some countries.
  • Multidrug-resistant malaria is a widespread and recurring problem, and while highly-effective artemisinin-based combination therapies (ACTs) have been introduced to treat drug-resistant strains, evidence suggests ACT resistance is occurring in parts of Asia and Africa.9 Resistance to insecticides has emerged as a problem in Africa, the Americas, Eastern Mediterranean, South-East Asia, and the Western Pacific.10
  • Certain groups, particularly pregnant women and children, are more vulnerable. Making up 76% of all malaria deaths in the Africa region, children under five are especially at-risk of malaria infection, because they lack developed immune systems to protect against the disease. Other high-risk groups include people living with HIV/AIDS, travelers, refugees, displaced persons, and migrant workers entering endemic areas.

Interventions

Malaria control efforts involve a combination of prevention and treatment strategies and tools, such as:

  • insecticide-treated bed nets (ITNs),11
  • indoor residual spraying (IRS) with insecticides,
  • diagnosis and treatment with antimalarial drugs, particularly artemisinin-based combination therapies (ACTs),12
  • intermittent preventive treatment in pregnancy (IPTp, a drug treatment for pregnant women that prevents complications from malaria for a woman and her unborn child),
  • perennial malaria chemoprevention (PMC, formerly called intermittent preventive treatment in infants (IPTi), a drug treatment aimed at reducing adverse effects of malaria in children belonging to age groups at high risk of severe malaria), and
  • seasonal malaria chemoprevention (SMC, a treatment course administered at monthly intervals to children belonging to age groups at high risk of severe malaria during the high malaria transmission season).

More recently, in 2021, the World Health Organization (WHO) recommended, and in 2022 prequalified, the first malaria vaccine (RTS,S/AS01 or RTS,S) and in 2023 recommended and prequalified a second malaria vaccine (R21/Matrix-M or R21), both of which have been shown to be safe and effective in preventing malaria in children during clinical trials.13 As of February 2026, 25 countries offered these vaccines through routine childhood immunization programs, with more planning to introduce or scale them up, and across these countries, over 10 million children per year are targeted for malaria vaccination.14 Roll-out of these vaccines will depend on financing and country decisions about whether to adopt the vaccines as part of their national malaria control strategies, among other things.

Access to prevention and treatment services has grown over time, as ITN coverage has increased and the number of ACT treatments procured by the public and private sectors has expanded substantially.15

Global Goals

Since the late 1990s, new initiatives and financing mechanisms have helped increase attention to malaria and contributed to efforts to achieve global goals; these include the RBM Partnership to End Malaria, a global framework established in 1998 for coordinating malaria efforts among donor governments, major UN agencies, international organizations, and affected countries, among others; and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), an independent, international financing institution established in 2001 that provides grants to countries to address TB, HIV, and malaria (see the KFF fact sheet on the U.S. and the Global Fund).16

These and other efforts work toward achieving major global malaria goals that have been set through:

  • Sustainable Development Goals (SDGs). Adopted in 2015, the SDGs aim to end the malaria epidemic by 2030 under SDG Goal 3, which is to “ensure healthy lives and promote well-being for all at all ages.”17
  • Global Technical Strategy for Malaria (GTS). Developed in close alignment with the RBM Partnership and adopted by the World Health Assembly in 2015, the GTS includes the goals of reducing malaria incidence and mortality rates by at least 90% by 2030, eliminating the disease in at least 35 new countries, and preventing the disease’s re-establishment in countries that are malaria free.

With these goals, the GTS sets out a vision for countries to accelerate progress towards malaria elimination, and globally, more countries are moving towards elimination. Between 2000 and 2024, 26 countries (Algeria, Argentina, Armenia, Azerbaijan, Belize, Bhutan, Cabo Verde, China, Egypt, El Salvador,  Iraq, Kazakhstan, Kyrgyzstan, Malaysia, Maldives, Morocco, Oman, Paraguay, Saudi Arabia, Sri Lanka, Syrian Arab Republic, Tajikistan, Turkey, Turkmenistan, United Arab Emirates, and Uzbekistan) that were malaria endemic in 2000 have attained three consecutive years of zero indigenous malaria cases and are therefore recognized as having eliminated the disease.18 In 2024, of 80 malaria-endemic countries, 46 countries worldwide were reported to have been nearing elimination.19Most recently, in March 2024, WHO along with Ministers of Health in Africa and other partners convened a Malaria Ministerial Conference and signed a declaration committing to accelerating action to end deaths from malaria.20

U.S. Government Efforts

Current Status

Involved in global malaria activities since the 1950s, the U.S. government (U.S.) has historically been the largest government donor to malaria efforts.21 It is also the largest donor to the Global Fund, which in turn is the largest overall funder of malaria efforts in the world.22 Since the beginning of the second Trump administration, however, the U.S. global health response has undergone significant shifts, disruption, and retraction, fundamentally altering the global health landscape and U.S. global malaria efforts through the President’s Malaria Initiative (PMI) in particular. Now, as the Trump administration reorganizes foreign aid, it is unclear what the future holds for PMI; multilateral cooperation on malaria (particularly after the U.S. withdrawal from the World Health Organization, or WHO; see below); and malaria vaccine roll-out (especially after the U.S. announced it will withhold funding from Gavi). Additionally, the future of U.S. support for U.S. global malaria research efforts is uncertain as the Trump administration reduces and eliminates foreign research grants. (See the KFF fact sheet on the status of PMI and other U.S. malaria efforts.)

More recently, in September 2025, the State Department released its “America First Global Health Strategy,” which details how the U.S. intends to engage in global health moving forward, including through bilateral health agreements, or Memorandums of Understanding (MOU), with partner countries (see the KFF tracker on these agreements). The strategy is focused on a subset of U.S. global health areas, including malaria, and reemphasizes the U.S. commitment to support the goals laid out by the GTS. The strategy does not, however, mention PMI, and it is unclear how much emphasis will be on malaria efforts going forward, including whether the funding appropriated by Congress for malaria will fully be spent by the administration.

History

The U.S. government’s international response to malaria began in the 1950s through activities at the U.S. Centers for Disease Control and Prevention (CDC) and U.S. Agency for International Development (USAID); early efforts focused on technical assistance but also included some direct financial support for programs overseas.

Starting in the early 2000s, the U.S. assigned a heightened priority to and provided greater funding for bilateral and multilateral malaria efforts. In 2003, the U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 (the legislation that created PEPFAR, the expanded U.S. government response to global AIDS) authorized five years of funding for bilateral malaria efforts and the Global Fund. In 2005, the U.S. launched the President’s Malaria Initiative (PMI), a five-year effort to address malaria in 15 hard-hit African countries, which has since been extended and expanded. In 2008, the Lantos-Hyde U.S. Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008 (which reauthorized PEPFAR) authorized another five years of funding and codified the position of the U.S. Global Malaria Coordinator.23 (See the KFF fact sheet on PEPFAR, the KFF fact sheet on the Global Fund, the KFF brief on PEPFAR reauthorization legislation, and the KFF dashboard monitoring progress toward global malaria targets in PMI countries.)

President’s Malaria Initiative (PMI)24

Launched in 2005, the President’s Malaria Initiative (PMI) was an interagency initiative to address global malaria led by USAID, until USAID’s recent dissolution, and implemented in partnership with CDC. It was overseen by a U.S. Global Malaria Coordinator, who was appointed by the President and reported to the USAID Administrator, and an Interagency Advisory Group made up of representatives from USAID, CDC, the National Institutes of Health (NIH), the Department of Defense (DoD), the State Department, the Peace Corps, the National Security Council, and other U.S. government agencies.25 USAID served as the lead implementing agency for U.S. global malaria efforts, primarily through PMI, with other agencies also carrying out malaria activities. Collectively, prior to the second Trump administration, U.S. bilateral activities reached approximately 30 countries.26 Now, amid the reorganization of foreign aid and dissolution of USAID, it is unclear how much of a focus on and funding for malaria will continue.

Goals

In 2021, the U.S. released the President’s Malaria Initiative Strategy 2021-2026; its goals included:

  • reducing malaria mortality by one-third from 2015 levels in high-burden PMI-supported countries,27
  • achieving a greater than 80% reduction from PMI’s original 2000 baseline levels,
  • reducing malaria morbidity in PMI-supported countries with high and moderate malaria burden by 40% from 2015 levels,28 and
  • assisting at least ten PMI-supported countries to meet the WHO criteria for national or sub-national elimination and at least one country in the Greater Mekong subregion to reach national elimination.

The strategy also stated that these efforts contribute to longer term goals, such as elimination of malaria in a growing number of countries, and aligns with global priorities.29 Today, these PMI goals are not reflected in the America First Global Health Strategy, although it  does reiterate the U.S. commitment to support the global malaria goals laid out by the GTS.

Key Activities30

Prior to the current administration, PMI activities focused on expanding access to and the use of six key malaria control interventions: insecticide-treated bed nets (ITNs), indoor residual spraying (IRS) with insecticides, entomological monitoring, intermittent preventive treatment in pregnancy (IPTp),31 diagnosis of malaria and treatment with artemisinin-based combination therapies (ACTs), and seasonal malaria chemoprevention (SMC).32

They also included a range of malaria control activities, including technical assistance to affected countries, monitoring and evaluation, supply chain management, and commodity procurement (since the start of PMI, U.S. support for commodities, such as ITNs, insecticides, and antimalarial drugs, like ACTs, has increased significantly33). Additionally, PMI supported activities in the following areas: behavior change communication, health systems strengthening, monitoring and evaluation, operational research, elimination, and community health.34

USAID had also supported regional efforts in Latin America and the Caribbean, including providing technical assistance to support countries in tailoring their approaches for malaria control through its Amazon Malaria Initiative.35 CDC provided technical assistance to these regional efforts and was also designated as the WHO Collaborating Center for Prevention and Control of Malaria,36 though with the U.S. withdrawal from WHO, the future of this partnership remains an open question (see also the KFF fact sheet on the U.S. and WHO). It also remains to be seen how announcements of global health reductions at CDC and the withholding of funding to Gavi could further affect malaria control efforts, including the roll-out of the malaria vaccine.

Additionally, NIH and DoD have been involved in malaria research and development (R&D). NIH has been the lead agency for U.S. malaria R&D efforts (including its International Centers of Excellence for Malaria Research program, which established a global network of malaria research centers in 2010 to support research activities in malaria-endemic countries).37 DoD also supported extensive R&D efforts as well as worldwide malaria disease surveillance, and technical assistance and capacity building with local partners.38 

Countries Reached

Prior to the current administration, PMI spanned 27 sub-Saharan African “focus countries” (gradually scaled up from three countries in FY 2006), as well as three countries in Southeast Asia under the PMI Greater Mekong Subregion regional initiative.39 Focus countries were selected based on the following criteria:40

  • high malaria burden,
  • alignment of National Malaria Control Plan (NMCP) with WHO standards,
  • country capacity to implement national control policies,
  • willingness to partner with the US in fighting malaria, and
  • involvement of other international donors (e.g., Global Fund; World Bank).

Both USAID and CDC stationed staff in each PMI focus country, though USAID staff were recalled to the U.S. due to the Trump administration’s dissolution of USAID and reorganization of foreign assistance.

Beyond PMI, the Amazon Malaria Initiative spanned several countries in Latin America and the Caribbean, and other U.S. activities may reach more countries. For example, CDC and USAID had carried out activities in additional countries in sub-Saharan Africa, the Caribbean, and Asia.41

Multilateral Efforts

The U.S. has partnered with international institutions providing support for global malaria funding mechanisms. Key partners have included WHO (although the second Trump administration officially withdrew the U.S. as a member of WHO, halting governance participation, technical assistance, and funding to the organization), the RBM Partnership, and the World Bank. Additionally, the U.S. government is the largest donor to the Global Fund, which has signed over $22 billion in funding for malaria programs worldwide and is the largest overall funder of global malaria efforts.42

Funding43

U.S. funding for malaria, which is specified by Congress in annual appropriations bills and includes support for PMI as well as other malaria control efforts and research activities, has increased slightly over the past decade from $963 million in FY 2017 to approximately $1 billion in FY 2026 (see figure for the latest information). Additional U.S. support for malaria activities is provided through its contribution to the Global Fund. (See the KFF fact sheet on the U.S. Global Health Budget: Malaria/PMI and the KFF budget tracker for more details on historical appropriations for U.S. global malaria efforts.)

Most U.S. bilateral funding for malaria has been provided through the Global Health Programs (GHP) account at USAID with additional funding provided through NIH, CDC, and DoD. In FY 2026, with the dissolution of USAID, funding through the GHP account shifted to the State Department. The majority of U.S. malaria funding has been directed to PMI focus countries, with additional funding directed to other bilateral and regional malaria efforts as well as malaria research activities. It is still unclear, however, whether the funding appropriated by Congress for malaria will fully be spent by the administration.

U.S. Funding for Global Malaria, FY 2017 - FY 2026 (Column Chart)

Endnotes


  1. WHO, World Malaria Report 2025, 2025. ↩︎
  2. WHO, World Malaria Report 2025, 2025. WHO, “Malaria fact sheet,” webpage, Dec. 2025, https://www.who.int/en/news-room/fact-sheets/detail/malaria. ↩︎
  3. CDC Malaria website, https://www.cdc.gov/malaria/hcp/clinical-features/ ↩︎
  4. M. Tanner, D. de Savigny, “Malaria Eradication Back on the Table,” Bulletin of WHO, Vol. 86, No. 2, 2008. ↩︎
  5. Launched by the World Health Organization, the United Nations Children’s Fund, the United Nations Development Programme, and the World Bank “to convene and coordinate an inclusive, multisectoral response to control, eliminate and ultimately eradicate malaria.” RBM Partnership to End Malaria, “RBM Partnership to End Malaria About Us,” webpage, https://endmalaria.org/who-we-are/about-us. ↩︎
  6. M. Tanner, D. de Savigny, “Malaria Eradication Back on the Table,” Bulletin of WHO, Vol. 86, No. 2, 2008; WHO, World Malaria Report 2025, 2025. ↩︎
  7. WHO, World Malaria Report 2025, 2025; M. Tanner and D. de Savigny, “Malaria Eradication Back on the Table,” Bulletin of WHO, Vol. 86, No. 2, 2008; RBM, The Global Malaria Action Plan, 2008; K. Senior, “Climate Change and Infectious Disease: A Dangerous Liaison?”, The Lancet. Vol. 8, No. 2,  2008; CDC, “Preventing Malaria While Traveling,” webpage, https://www.cdc.gov/malaria/prevention/index.html. ↩︎
  8. WHO, World Malaria Report 2025, 2025; WHO, “Malaria fact sheet,” webpage, Dec. 2025, https://www.who.int/en/news-room/fact-sheets/detail/malaria. ↩︎
  9. WHO, World Malaria Report 2025, 2025; Global Plan for Artemisinin Resistance Containment (GPARC), 2011; Emergency Response to Artemisinin Resistance in the Greater Mekong Subregion: Regional Framework for Action 2013-2015, April 2013; Status report on artemisinin resistance and ACT efficacy, December 2019, accessed here: https://apo.who.int/publications/i/item/status-report-on-artemisinin-resistance-and-act-efficacy; “Malaria: Artemisinin partial resistance” webpage, https://www.who.int/news-room/questions-and-answers/item/artemisinin-resistance. WHO, Strategy to respond to antimalarial drug resistance in Africa, 2022. ↩︎
  10. To address insecticide resistance, the WHO issued updated guidance in 2023 recommending the use of dual active ingredient ITNs. WHO, Press release: WHO publishes recommendations on two new types of insecticide-treated nets, March 2023. ↩︎
  11. In 2023, WHO published recommendations on two new types of dual active ingredient insecticide-treated mosquito nets, designed to provide greater protection against malaria than previously recommended nets. WHO, World Malaria Report 2025, 2025. ↩︎
  12. For a detailed description of WHO’s recommendations on the use of drugs to prevent malaria in high-risk groups, please see WHO’s Guidelines for Malaria. WHO, Guidelines for Malaria, August 2025. ↩︎
  13. Vaccines that are added to WHO’s prequalification list are endorsed by WHO as having gone through comprehensive evaluation to determine that the vaccine is safe and effective. WHO, Press release: WHO recommends groundbreaking malaria vaccine for children at risk, October 2021. WHO, Press release: WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization, October 2023. WHO, Press release: WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease, December 2023. ↩︎
  14. WHO,  “Malaria vaccines (RTS,S and R21)” webpage, accessed: https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine. ↩︎
  15. WHO, Malaria Prevention Works: let’s close the gap, April 2017. WHO, World Malaria Report 2025, 2025. ↩︎
  16. RBM Partnership to End Malaria website, https://endmalaria.org/; Global Fund website, https://www.theglobalfund.org/en/. ↩︎
  17. UN, Transforming our world: the 2030 Agenda for Sustainable Development, 2015. ↩︎
  18. WHO, World Malaria Report 2025, 2025. ↩︎
  19. Countries that were malaria endemic in 2000 and reported fewer than 10,000 malaria cases are said to be “nearing elimination.” WHO, World Malaria Report 2025, 2025. ↩︎
  20. WHO, Press release: African health ministers commit to end malaria deaths, March 2024. ↩︎
  21. WHO, World Malaria Report 2025, 2025. ↩︎
  22. KFF: Global Financing for Malaria: Trends & Future Status, 2014; Mapping the Donor Landscape in Global Health: Malaria, 2013; World Malaria Report 2025, 2025. KFF analysis of OECD DAC CRS database, December 2025. ↩︎
  23. U.S. Congress, Public Law 108-25, May 27, 2003; U.S. Congress, Public Law 110-293, July 30, 2008. ↩︎
  24. PMI website, https://web.archive.org/web/20250117222257/https:/www.pmi.gov/; USAID, “The President’s Malaria Initiative,” fact sheet, May 2023; PMI, The President’s Malaria Initiative: Eighteenth Annual Report to Congress, 2024; PMI, FY 2017 Greater Mekong Subregion Malaria Operational Plan, 2017; CDC, “President’s Malaria Initiative,” webpage, https://web.archive.org/web/20240424052020/https:/www.cdc.gov/malaria/malaria_worldwide/cdc_activities/pmi.html. ↩︎
  25. PMI. “Leadership” webpage, accessed: https://web.archive.org/web/20250122153738/https:/www.pmi.gov/about-us/#leadership. ↩︎
  26. KFF analysis of data from the U.S. Foreign Assistance Dashboard website, http://www.foreignassistance.gov, accessed February 2025. PMI, Eighteenth Annual Report to Congress, 2024. CDC, “Malaria’s Global Malaria Activities” webpage, https://web.archive.org/web/20240303033903/https:/www.cdc.gov/malaria/malaria_worldwide/cdc_activities/index.html. ↩︎
  27.  The countries targeted by PMI that are considered high burden include Angola, Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ghana, Guinea, Liberia, Mali, Mozambique, Niger, Nigeria, and Sierra Leone. PMI, President’s Malaria Initiative Strategy 20212026, 2021. ↩︎
  28. The countries targeted by PMI that are considered moderate burden include Madagascar, Malawi, Tanzania, Uganda, and Zambia. PMI, President’s Malaria Initiative Strategy 20212026, 2021. ↩︎
  29. PMI, President’s Malaria Initiative Strategy 2021-2026, 2021. ↩︎
  30. PMI, “What We Do,” webpage, https://web.archive.org/web/20241219104218/https:/www.pmi.gov/what-we-do/. ↩︎
  31. Another preventive treatment includes PMC in countries where that treatment is relevant. To date only Sierra Leone had prioritized PMC for PMI support in their NMCPs. PMI, President’s Malaria Initiative Technical FY 2024 Guidance. ↩︎
  32. SMC is only recommended for geographic regions where the malaria transmission season is four months or less. PMI, President’s Malaria Initiative Technical FY 2024 Guidance. ↩︎
  33. PMI, “Malaria Operational Plans,” webpage, https://web.archive.org/web/20240618003157/https:/www.pmi.gov/resources/malaria-operational-plans-mops/. ↩︎
  34. PMI, “What We Do,” webpage, https://web.archive.org/web/20241219104218/https:/www.pmi.gov/what-we-do/. ↩︎
  35. USAID, “Malaria: Countries,” webpage, https://web.archive.org/web/20231004093249/https:/www.usaid.gov/global-health/health-areas/malaria/countries. CDC, “CDC’s Global Malaria Activities” webpage, https://web.archive.org/web/20240303033903/https:/www.cdc.gov/malaria/malaria_worldwide/cdc_activities/index.html. ↩︎
  36. CDC, “CDC’s Malaria Program,” fact sheet, 2023. ↩︎
  37. NIAID: “Malaria,” webpage, https://www.niaid.nih.gov/diseases-conditions/malaria; “International Centers of Excellence for Malaria Research (ICEMR),” webpage, https://www.niaid.nih.gov/research/excellence-malaria-research↩︎
  38. KFF, The Department of Defense and Global Health: Infectious Disease Efforts, 2013. ↩︎
  39. In September 2017, PMI announced the addition of five new focus countries, bringing the number of PMI programs to 24 in sub-Saharan Africa. PMI. Press release: PMI Launches and Expands in West and Central Africa, September 2017; In April 2023, PMI announced its intention to expand to three more sub-Saharan African countries, increasing the total number of partner countries reached to 30 (27 in Sub-Saharan Africa and 3 in the Greater Mekong Region); the three additional countries include Burundi, The Gambia, and Togo. PMI, U.S. President’s Malaria Initiative Announces Plans to Expand to New Partner Countries, April 2023; PMI, “Where We Work,” webpage, https://web.archive.org/web/20250122154423/https:/www.pmi.gov/where-we-work/. ↩︎
  40. PMI, 2011 PMI Fifth Annual Report, April 2011. ↩︎
  41. CDC, “CDC’s Global Malaria Activities,” webpage, https://web.archive.org/web/20240303033903/https:/www.cdc.gov/malaria/malaria_worldwide/cdc_activities/index.html. ↩︎
  42. Global Fund, Global Fund Data Explorer: https://data.theglobalfund.org/; accessed January 2026. KFF analysis. ↩︎
  43. KFF analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and the U.S. Foreign Assistance Dashboard website, www.foreignassistance.gov. ↩︎

HHS Public Health Policy Actions Under the Trump Administration 2025-2026

Published: Mar 19, 2026

Note: Originally published on Nov. 12, 2025, this resource is updated as needed, most recently on March 19, 2026, to reflect additional developments. 

Since assuming office for a second term, President Trump and officials in his administration have instituted numerous policy actions through the Department of Health and Human Services (HHS) affecting public health in the U.S. This resource lists and briefly describes key actions in the order in which they were first issued, reported or announced, with subsequent linked actions and related outcomes also included with each entry. As new policy changes occur, they will be added. 

This resource is not meant to be exhaustive of all administration actions related to public health, as many other federal policy changes – including outside of HHS – have public health implications but are not captured here.

Additional KFF resources on administrative actions related to global health, LGBTQ+ health, and mental health and substance abuse are also available.

Date

|

Action/Description

January 20, 2025Presidential Executive Orders precipitate removal of some HHS websites and health data.
– In the first days of his second term President Trump issued a number of Executive Orders (EOs), including EOs that revoked many Biden administration orders and programs, and instituted new federal guidance related to “gender ideology,” “diversity, equity, and inclusion (DEI),” and “merit-based opportunities.” These EOs have implications for public health, particularly related to the collection and presentation of data and websites by the federal government. For example, in response to the EOs, HHS began to remove thousands of websites and numerous federal databases with public health information deemed to be related to DEI, LGBTQ, reproductive health, HIV/AIDS research, health disparities, and more, and limited some data collection and analysis in these areas. A lawsuit was filed to reverse these removals, and some information has been restored over time. In September, the administration agreed to restore all previously removed health-focused websites and data to versions that had existed on January 29, 2025.
February 7, 2025NIH announces change to indirect cost rate guidance.
– As part of grants for health research, the National Institutes of Health (NIH) provides “indirect cost” funding to grant recipients, which supports administration and facilities costs at grantee institutions. On February 7, NIH announced it would apply a new 15% “standard indirect cost rate” on all grants, which would apply to any new grants and to existing grants for expenses as of February 10, 2025. This was challenged in federal court and federal judges placed holds on the policy, first through a temporary restraining order affecting 22 states on February 10, a nationwide preliminary injunction on March 5, and a permanent injunction on April 4; prior rates still apply for the time being. The administration appealed the ruling and legal proceedings continue. If implemented, a 15% indirect cost rate would be a much lower rate compared to historical NIH rates and would amount to a significant cut in funding for institutions performing NIH-sponsored health research.
February 13, 2025Robert F. Kennedy, Jr. confirmed as HHS Secretary under President Trump.
– The Senate voted 52-48, along party lines, to confirm Robert F. Kennedy, Jr. as the Secretary of Health and Human Services.
February 13, 2025President Trump issues Executive Order (EO) establishing MAHA policy agenda and MAHA Commission.
– The EO outlines the purpose and objectives of the Trump administration’s Make American Healthy Again (MAHA) efforts. Stating that the U.S. must “re-direct our national focus…toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease,” it directs federal agencies to “aggressively combat” mental health disorders, obesity, diabetes, and other conditions. It also establishes the MAHA Commission to advise the President, naming Secretary Kennedy as Chair. The EO directs the Commission to submit an assessment on how to combat the “childhood chronic disease crisis” within 100 days, and a strategy to address the crisis within 180 days, setting in motion processes to develop further public health strategies and plans (discussed in other entries below). 
February 14, 2025White House, DOGE initiate “reduction in force (RIF)”, including for HHS personnel.
– The EO outlines the purpose and objectives of the Trump administration’s Make American Healthy Again (MAHA) efforts. Stating that the U.S. must “re-direct our national focus…toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease,” it directs federal agencies to “aggressively combat” mental health disorders, obesity, diabetes, and other conditions. It also establishes the MAHA Commission to advise the President, naming Secretary Kennedy as Chair. The EO directs the Commission to submit an assessment on how to combat the “childhood chronic disease crisis” within 100 days, and a strategy to address the crisis within 180 days, setting in motion processes to develop further public health strategies and plans (discussed in other entries below). 
February 14, 2025President Trump issues Executive Order prohibiting federal funding to schools and universities with COVID-19 vaccine requirements.
– The EO requires HHS to work with the Department of Education to prohibit COVID-19 mandates in schools, by issuing guidelines for compliance and barring federal funds from going to any educational agency, K-12 school, or institution of higher education that requires COVID-19 vaccination to attend in-person education programs (educational vaccine mandates are set at the state level). Educational vaccine requirements are set at the state and local levels. At the time the EO was released in February, no state required K-12 students to be vaccinated against COVID-19 while 15 colleges required Covid vaccines for students. However, by March 14, 2025 all of those colleges had ended their COVID-19 vaccine requirements for students.
February 18, 2025Secretary Kennedy announces public health policy priorities during HHS welcome ceremony.
– In his first remarks to HHS staff, Secretary Kennedy announces the public health priorities for his tenure. This include investigating the childhood vaccine schedule, tackling corruption and promoting transparency, and addressing a “chronic disease epidemic” especially in children, which he says may be linked to pesticides, food additives, antidepressants, microplastics, cellphone emissions, and other factors.
February 28, 2025Secretary Kennedy issues new rule ending public comment requirement for HHS grants and contracts.
– The new rule rescinds a prior HHS policy on “Public Participation in Rule Making” (the “Richardson Waiver,” dating back to 1971) and “re-aligns the Department’s rule-making procedures with the Administrative Procedure Act.”  As a result, “matters relating to agency management or personnel or to public property, loans, grants, benefits, or contracts” are exempt from the notice and comment procedures. This removes what had been a key step in the rulemaking process requiring public notification and a comment period. For example, changes to HHS policies related to work requirements for Medicaid and NIH funding would no longer require public comments under the new rule. This could streamline implementation of HHS policy, but also reduce public visibility on changes before they take effect.  Some lawmakers and public health focused groups have asked HHS to return to the prior requirements under the Richardson Waiver. 
March 7, 2025HHS announces that CDC will conduct a study of factors contributing to the rise in autism in the U.S.
– In statements to the press, HHS officials indicate CDC will initiate a study looking at the factors that are contributing to the rise in autism diagnoses in the U.S.. To date, no new CDC study results on this topic have been released though in a related development, in September 2025 President Trump and HHS leadership announced at a press conference and through a White House Fact Sheet that they believe there is a link between acetaminophen (e.g., Tylenol) use in pregnancy to autism (further details provided below). President Trump and Secretary Kennedy both have a history of linking vaccines and autism, even though there is no evidence of such a link.
March 13, 2025Food and Drug Administration (FDA) releases guidance on 2025-2026 influenza vaccine composition.
– The FDA guidance identifies which influenza virus strains manufacturers should use as components of 2025-2026 influenza vaccines. To develop these recommendations, FDA convened meetings of federal scientific and public health experts, including from FDA, CDC, and Department of Defense, but did not consult with the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) or other professional groups outside the government. FDA had canceled the scheduled VRBPAC meeting on this topic, and the lack of input from outside experts was a break from past years’ practices. In addition, in past years there was active participation and coordination between U.S. federal experts and global technical experts working under the auspices of the World Health Organization (WHO), but official communications with WHO-linked experts has been curtailed since the Trump administration announced in January 2025 that the U.S. was withdrawing its membership from the UN agency.
March 17, 2025NIH initiates termination of numerous grants for HIV prevention and treatment programs.
– The canceled NIH grants include support for researchers investigating use of PrEP, medication used pre-exposure to prevent HIV infections, and programs focused on HIV/AIDS in adolescents and young adults. Even as the first Trump administration supported HIV/AIDS prevention and treatment efforts, including through a highly visible federal effort to “end the HIV epidemic” in the U.S. by 2030, these same programs have now been targeted for cuts (further details below).   
March 17, 2025HHS removes Surgeon General warning declaring gun violence a public health crisis.
– The HHS website was changed, removing a 2024 advisory from the Surgeon General on the public health impacts of gun violence. In addition to removing the Surgeon General’s warning, the administration has rolled back a number of gun safety policies in place during the Biden administration. The White House Office of Gun Violence Prevention, established during the Biden administration was shut down in early 2025. Further, significant numbers of staff at CDC’s Injury Center, which collects data on violent deaths and injuries, and CDC’s Division of Violence Prevention have been let go as part of the Trump administration’s reduction in force efforts.
March 25, 2025HHS and CDC seek to pull back $11 billion in supplemental COVID-19 and public health funding from state and local health departments.
– In a statement, HHS says it intends to pull back $11.4 billion in supplemental funding that had been provided by Congress for state and local public health departments through CDC for pandemic response activities. Following the announcement, on April 1, a group of 23 mostly Democratic-led states sued the Trump administration over the attempt to pull back this funding.  On April 3, a federal judge placed a temporary block on the administration’s actions, and on May 16, another federal judge indefinitely blocked the administration from enacting its funding pull back for the states that are part of the lawsuit. As of late August 2025, almost 80% of the funds initially targeted for cuts by the Trump administration had been restored for the 23 states that won in court. However, funding has not been restored to the remaining states, the majority of which are Republican-led.
March 27, 2025HHS announces a major re-organization and job cuts plan.
– HHS announces plans for a major restructuring of the department, in accordance with President Trump’s February 26 EO on “Implementing the President’s ‘Department of Government Efficiency’ Workforce Optimization Initiative.” The announcement says HHS will create an Administration for a Healthy America (AHA), which would combine several existing HHS offices including the Office of the Assistant Secretary of Health (OASH, which contains the Surgeon General’s Office), the Health Research and Services Administration (HRSA), the Substance Abuse and Mental Health Services Administration (SAMSHA), the Agency for Toxic Substance and Disease Registry (ATSDR), and the National Institute for Occupational Safety and Health (NIOSH). In addition, the Administration for Strategic Preparedness and Response (ASPR) at HHS would be moved under CDC. The announcement also says HHS will reduce its workforce by eliminating 10,000 full-time positions. Combined with other reduction in force efforts, a total of 20,000 HHS workers are expected to lose their jobs.

On May 5, a coalition of 19 Democratic-led states and the District of Columbia filed a lawsuit against the mass firing of federal health workers and re-organization of HHS. On May 10, a court ordered a temporary pause on sweeping federal firings at HHS and other agencies. On July 1, a federal judge blocked mass firings at HHS, saying they are likely unlawful. However, on July 8 the Supreme Court overturned the lower court decisions, allowing the Trump administration to proceed with job cuts. As of August it is estimated that over 20,000 jobs at HHS have already been cut, meaning the administration already met its initial workforce reduction goal.

Regarding re-organization, some organizational changes have been implemented at HHS, with major cuts or closures to public health related offices such as the HHS Office of Infectious Diseases & HIV Policy, the HHS Office of Minority Health, and HRSA’s Bureau of Primary Health Care.  However, other proposals such as the formation of an Administration for a Healthy America (AHA), have not yet been implemented. Implementing AHA to the extent proposed is likely to require approval from Congress, though so far Congress has not acted on legislation codifying these proposals.
March 31, 2025HHS withholds portion of Title X family planning service grants. 
– HHS notifies one in five current grantees of the federal Title X family planning program that a portion of their funding would be temporarily withheld. This funding freeze affects all nine Planned Parenthood grantees, in addition to 7 other nonprofit grantees, and it is estimated that a total of 879 clinics (24% of all Title X clinics) in 23 states are affected. After several months, funds were reinstated to some organizations, but the Planned Parenthood grantees have still not had their funding reinstated.
April 1, 2025HHS ends federal support for the “Safe to Sleep” program, which focuses on prevention of infant deaths during sleep.
– The Trump Administration ends federal participation in Safe to Sleep, a national campaign that focused on educating parents of newborns about safer sleeping practices for infants that can prevent death. The program, supported through the NIH’s National Institute of Child Health and Human Development (NICHD) Office of Communications in recent years, had been in existence for over 30 years and had contributed to a major decline in sudden infant deaths. The NICHD office was eliminated on April 1, along with federal support for “Safe to Sleep.”
April 2, 2025HHS requires CDC to reduce contract spending by $2.9 billion as part of DOGE cost reduction efforts.
– According to reports, HHS orders CDC to reduce its contract spending by $2.9 billion by April 18.CDC contract funding has been used to support several services at the agency including security, cleaning, and computers/technology. The sudden requirement to cut this spending by approximately 35% affects CDC operations. 
April 7, 2025HHS Secretary Kennedy announces changes to fluoride policies.
– Secretary Kennedy announces a plan to implement a number of changes to federal policy related to water fluoridation, including stating that CDC will stop recommending water fluoridation as a public health intervention (though to date, HHS and CDC still recommend community water fluoridation). In addition, Kennedy says the defunct Community Preventive Services Task will be revived and reconvened, with a goal of studying and making recommendations about water fluoridation. Kennedy also called on states to ban fluoride in their drinking water. Already this year Utah and Florida have banned community water fluoridation, the first states ever to do so.
April 17, 2025FDA informs Pfizer/Moderna that mRNA COVID vaccines will require an expanded warning label about myocarditis.
– In letters sent April 17, the FDA informs Pfizer and Moderna they must alter the warning labels for their COVID-19 mRNA vaccines to include expanded risks for myocarditis and pericarditis. Previously, the warning labels for these vaccines noted risks for these conditions for those aged 18 to 24 years (Moderna) and 12 to 17 years (Pfizer). However, updated labels are required to include new language saying “the observed risk of myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines has been highest in males 12 through 24 years of age” and that “persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common.”  According to FDA, the labels must also include more information about these conditions and their health risks.  Since the letters were sent, the companies have complied with the new FDA requirements. FDA approved the updated label language on June 25.
April 22, 2025FDA and HHS announce measures to phase out use of petroleum-based food dyes.
– FDA and HHS announce a series of steps the federal government will take to remove petroleum-based synthetic dyes from the U.S. food supply. These actions include initiating a process to revoke federal authorization for two such dyes and planning phase-outs by the food industry for others. In addition, the government will support research on food additives and children’s health and authorize natural alternative coloring options. Under the current plan, the phase-outs will occur through voluntary action taken by food companies.
May 1, 2025HHS announces a $500 million investment in a “next generation universal vaccine platform.”
– HHS and NIH announce that $500 million in funding will be directed to a new effort  to develop a “universal vaccine platform for pandemic-prone viruses.” The platform uses inactivated whole viruses, and is part of a broader federal effort to develop universal vaccines called “Generation Gold Standard.” The funds for this new investment appear to be re-purposed vaccine development funds from the Biden Administration’s NextGen initiative to develop next generation COVID-19 vaccines.
May 2, 2025White House Releases FY 2026 President’s Budget Request calling for major fundings cuts at HHS.
– The White House released an outline of the administration’s budget request for FY2026 and on May 30, the White House submitted the full Budget Request for FY2026 to Congress. The request proposes steep cuts to the HHS budget, including cuts for CDC, HRSA, SAMHSA, NIH, eliminating the Hospital Preparedness Program at ASPR, and reducing funding and cutting some programs focused on HIV/AIDS research and response. The budget request also asks Congress for $500 million to support a new “Administration for a Healthy America (AHA)” and MAHA-related priorities. The President’s Budget Request is only a proposal, as it is Congress that ultimately decides how much money the federal government appropriates. So far, Congressional spending bills for FY2026 have not included cuts to HHS of the magnitude requested by the President, and Congress has not provided the requested $500 million for AHA though budget negotiations continue.   
May 5, 2025White House Executive Order restricts funding and increases oversight for “gain of function” research at HHS.
– In an EO titled “Improving the Safety and Security of Biological Research” the White House cites concerns with federally funded “gain-of-function” (GOF) research on biological agents and states the Biden administration allowed dangerous GOF research to occur without sufficient oversight. The EO directs the Secretary of HHS to coordinate with other relevant Executive branch offices to establish guidance to end federal funding of “foreign entities” where GOF is being undertaken or in countries lacking oversight of GOF research. The EO requires the relevant Executive offices to submit updated policies and guidance for all federally supported GOF-related research, and to develop a strategy for managing risks of non- federally funded GOF research. The full implications of the EO are not yet clear, as the Executive branch offices must develop and implement specific guidance and regulations. According to outside experts, potential benefits of the EO include more transparency and stricter enforcement of dangerous research, while potential risks include hindering beneficial research that is not GOF and researchers choosing to curtail beneficial research to avoid potential repercussions under evolving federal restrictions.
May 20, 2025FDA leaders announce clinical trials will be needed for approval of certain new COVID vaccine formulations.
– In a medical journal article, FDA leaders indicate that going forward, for federal approval of new or updated COVID-19 vaccines (“boosters”) for use in individuals who are not considered at higher risk (defined as persons 65 or older or those with certain health conditions), will require vaccine makers to present evidence from randomized, placebo-controlled trials that demonstrate safety and efficacy. The announced policy is a departure from prior years when FDA did not require new trial data to authorize or approve boosters, but instead allowed approvals based on immune response evidence. The new policy could hinder investments by pharmaceutical companies in developing new COVID vaccine formulations, given the greater expense and time required to conduct new, full clinical trials.
May 22, 2025MAHA Commission Report on childhood chronic disease published.
– The first official report from the MAHA Commission (established by the February 13 EO discussed above) discusses factors contributing to a “chronic disease crisis” for U.S. children and provides a “call to action”. The report highlights four main drivers of the crisis: poor diet (primarily due to consumption of ultra-processed foods), exposure to chemicals, lack of physical activity and chronic stress, and “overmedicalization (excessive use of prescription drugs, such as antidepressants). The report calls for federal agencies to “close critical research gaps and guide efforts to better combat” these issues. It also says the MAHA Commission will develop and release a strategy in August (discussed below). The report expanded on the ideas initially outlined in the February EO and provided more details on Secretary Kennedy’s priorities to address chronic disease in children. There was some criticism of the report after its publication, with experts questioning some of the evidence and conclusions and pointing out significant errors and studies cited that did not exist, which indicated that artificial intelligence was likely used to help write the report. 
May 23, 2025Administration ends NIH funding for several HIV vaccine research projects. 
– NIH notifies two grant recipients working on broadly neutralizing antibody research for HIV vaccines of the cancelation of their funding.  The canceled grants supported early-stage vaccine development research that uses a different approach than other HIV vaccine candidates. Some other HIV vaccine candidates remain in the development pipeline and clinical trials continue, but the absence of this early-stage research could jeopardize the development of additional candidates going forward.
May 27, 2025HHS Secretary Kennedy announces CDC will no longer recommend COVID vaccines for healthy pregnant women and children.
– In a video post on X, Secretary Kennedy announces “the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule.” The announcement was a departure from the typical process for changing vaccine recommendations, which includes review and input from the Advisory Committee on Immunization Practices (ACIP) and a notification from the CDC Director. Initially, the implications of changing CDC guidance without ACIP input were unclear given that no-cost insurance coverage for vaccination is linked to ACIP and CDC recommendations. On May 30, CDC changed the language on its website for COVID-19 vaccines, removing its prior recommendation for pregnant women to be routinely vaccinated and stating that healthy children 6 months to 17 years old could be vaccinated in consultation with health care providers/parents – a recommendation known as “shared decision-making,” which would mean insurance would still have to cover such vaccinations. On July 7, a coalition of professional medical organizations filed a lawsuit against HHS over the new COVID-19 vaccine recommendations, saying the department did not follow federal procedures in making the change and also mislead the public on the issue (on January 6, 2026, a federal court confirmed these plaintiffs have standing to challenge HHS’s actions on the COVID-19 vaccine recommendations, allowing the case to proceed to arguments). On August 19, independent expert groups, including the AAP, issued their own recommendations for COVID vaccines in infants and young children in contrast with CDC’s new recommendations.  On Aug 22, ACOG issued their own recommendations for pregnant patients.
June 9, 2025HHS Secretary Kennedy announces removal of all sitting members of ACIP.  
– In a post on X and a subsequent HHS press notice, Secretary Kennedy announces that all 17 sitting members of the CDC’s Advisory Committee on Immunization Practices (ACIP) are dismissed, to be replaced with new members selected by the Secretary. Kennedy says the move is “prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda.” The HHS Secretary does have the discretion to remove and nominate ACIP members, though no previous Secretary has dismissed all ACIP members at once. In a subsequent X post on June 11, Kennedy announces the nomination of eight new members to ACIP, several of whom have been critical of COVID-19 vaccines and have expressed concerns about harms caused by vaccinations more generally. In a later press release from September 15, HHS announces five more members to be appointed to ACIP, including several with a history of criticism of COVID-19 vaccine policies. 
June 17, 2025FDA announces National Priority Vouchers for expedited regulatory review of new drugs that support “U.S. national interest.
– FDA announces a Commissioner’s National Priority Voucher (CNPV) program, which can be “redeemed by drug developers to participate in a novel priority program” that shortens regulatory review time from 10-12 months to 1-2 months. FDA says it will determine the availability of vouchers for companies that are aligned with the “national health priorities” of: addressing a health crisis in the U.S.; delivering more innovative cures for the American people; addressing unmet public health needs; and, increasing domestic drug manufacturing as a national security issue. On October 16, FDA announced the first nine CNPV recipients, and on November 6, announced six more recipients.  The impact of this new priority voucher program on speeding drug approvals and onshoring drug manufacturing capacity is as yet unclear. In addition, there are several other existing priority review processes at FDA so adding another could strain FDA staff capacity at the same time there has been significant reductions in FDA’s staff and budget.  These strains have already slowed FDA review times in general.
June 18, 2025FDA approves lenacapavir – a new HIV prevention drug.
– FDA approves Gilead Sciences’ lenacapavir, a new injectable PrEP drug that has been shown to be highly effective at preventing HIV infection, and which requires just one dose every 6 months, making it the first ever twice-a-year drug option for HIV prevention. In September, CDC issued clinical guidance for use of injectable lenacapavir as PrEP, though that guidance did not include reference to transgender people, a group intentionally included in the clinical trials and at increased risk of HIV. FDA’s approval also precipitated a review by the World Health Organization (WHO) and on October 6, WHO pre-qualified lenacapavir for prevention of HIV. WHO pre-qualification can speed regulatory approval for the drug in many low- and middle-income countries with a high burden of HIV/AIDS and can also allow for global health mechanisms like the Global Fund to Fight AIDS, Tuberculosis and Malaria to procure the drug.
June 25-26, 2025The newly reconstituted ACIP makes recommendations and policy changes related to RSV and influenza vaccines, and designates new workgroups on hepatitis B, MMRV, and the childhood immunization schedule.
– ACIP votes to recommend respiratory syncytial virus (RSV) injections for babies and RSV vaccine for people 50 and older, and a ban on the use of thimerosal in multi-dose influenza vaccine vials. ACIP also agrees to stand up three new workgroups that will review the U.S. childhood vaccination schedule, hepatitis B guidance, and combination MMRV vaccine.  Subsequently, on July 3, CDC issued new RSV guidance that mirrored ACIP recommendations. On July 23, Secretary Kennedy enacted ACIP’s recommendation on thimerosal, rescinding federal recommendations for any influenza vaccines containing thimerosal (a change that only affects a very small percentage of the overall influenza vaccine market that is comprised of multidose vials).
July 1, 2025HHS alters program requirements and withholds funding from sex education and teen pregnancy prevention programs.
– HHS notifies all Teen Pregnancy Prevention (TPP) program grantees and Personal Responsibility Education Program (PREP) grantees in 46 states and territories that their material must align with President Trump’s executive orders, including those that ban the promotion of gender inclusivity, risk losing federal funding. TPP is a national grant program that funds grantees to replicate, develop, test, and evaluate evidence-based approaches to prevent teen pregnancy, while PREP awards grants to state agencies to use evidence-based models in educating adolescents on both abstinence and contraception. In August, the Trump administration cancelled a $12.3 million PREP grant to California after state officials refused to revise curricula in compliance with the EOs. In September 2025, 16 states and D.C. sued HHS alleging that the new PREP grant conditions are unlawful, unconstitutional, and harmful to gender diverse youth. Similarly, a federal judge blocked the HHS policy changes for TPP in October 2025.
July 2, 2025CDC deactivates its emergency response for H5N1 influenza (bird flu) and limits tracking and reporting of data on bird flu infections in humans and animals.
– CDC ends its emergency response for H5N1 bird flu in the U.S., which had been active since April 4, 2024. CDC reports the change is due to a decline in animal infections and no reports of human cases since February 2025. CDC also says data on the number of people tested for H5N1 will be reported only monthly, and no further data on infection rates in animals will be reported on the CDC website. Even so, reporting from states showed the number of H5N1 cases in birds, which had declined over the summer, began to increase again in fall 2025. However, much of the federal research and response efforts for H5N1 have been closed down or significantly limited following funding and staff cuts and a prolonged government shutdown. The limited federal tracking and reporting of H5N1 infections can slow identification of outbreaks and potentially slow response times.
July 9, 2025HHS Secretary Kennedy cancels a scheduled meeting of the U.S. Preventive Services Task Force (USPSTF).
– Secretary Kennedy cancels a meeting of the USPSTF several days before it was scheduled to take place, with no reason given and no re-scheduled meeting date provided. Typically, the task force meets three times a year, though no meeting has yet occurred under Secretary Kennedy. USPSTF is responsible for reviewing and recommending preventive health services. USPSTF recommendations have implications for what services insurers must cover with no cost-sharing, under the Affordable Care Act (ACA). Such services can include screening tests, behavioral counseling, and medications that can prevent diseases and illness (other than vaccines, which are tied to ACIP recommendations). However, along with other parts of the ACA, USPSTF has faced court challenges. On June 27 (prior to Kennedy’s cancelation of the meeting), while the Supreme Court ruled the ACA requirement that insurers cover USPSTF-recommended services is indeed constitutional, it also found that the HHS Secretary has the power to add and remove USPSTF members at will, which underscores the possibility that Secretary Kennedy may choose to dismiss some or all of the existing USPSTF members and appoint new members (as Kennedy has done with ACIP), or simply not name any new members, and has the power to choose not to adopt USPSTF recommendations. In light of Kennedy’s cancellation and the Supreme Court ruling, 104 public health focused organizations called on Congress to “protect the integrity of the USPSTF” through legislative action. The subsequent USPSTF meeting was scheduled to occur in November but that was also canceled, with HHS citing the government shutdown as the reason. 
July 31, 2025FDA announces new safety label requirement for opioid pain medications.
– The FDA says will require safety labels on opioid medications so that users can better understand that risks of long-term opioid use. The updated labels should include a summary on the risk of addiction, misuse, and overdose, treatment guidance and the risk of higher doses, how to safely discontinue opioid use, drug interactions, digestive complications, and overdose reversal medications. Drug companies received notification letters and have 30 days to submit updated labels for review.
July 31, 2025HHS Secretary Kennedy swears in Susan Monarez as CDC Director.
– In a statement welcoming the newly Senate-confirmed CDC Director, Secretary Kennedy says Monarez has “unimpeachable scientific credentials” and he has “full confidence in her ability to restore the CDC’s role as the most trusted authority in public health.” However, 28 days later (on August 27) the White House removed Monarez from her position at CDC. According to Kennedy, she was removed because he lost trust in her ability to serve as CDC Director and to implement the policies of the Trump Administration. According to Monarez, she was removed because she would not provide “blanket approval” for vaccine policy changes in advance and would not fire, as requested by Kennedy, CDC employees without cause. On August 28, Secretary Kennedy announced in a letter to CDC staff that Deputy Health and Human Services Secretary Jim O’Neill would serve as acting CDC Director.
August 1, 2025Newly announced CDC policy prevents outside professional medical and public health organizations from participating in working group meetings of ACIP.
– Officials at HHS notify professional medical organizations such as the American Academy of Pediatrics (AAP), the American Medical Association (AMA), the American College of Obstetricians and Gynecologists (ACOG), and others that they will be excluded from joining ACIP working group discussions going forward. Professional groups representing medical doctors and other stakeholders in vaccine policies have long participated as non-voting members, including in ACIP working groups. Working groups are typically responsible for helping review available data about topics prior to ACIP meetings, and helping develop recommendation language for ACIP to vote on, as well as other activities in support of ACIP. While the outside groups can be present and can participate in full ACIP meetings, the new policy removes them from providing any input through working groups.
August 5, 2025HHS announces a “coordinated wind down” of $500 million in federal funding for mRNA vaccine research
– HHS announces that it will cancel and begin to wind down mRNA vaccine development activities funded through the Biomedical Advanced Research and Development Authority (BARDA). In total, HHS reports it is canceling 22 projects worth nearly $500 million because “these vaccines fail to protect effectively against upper respiratory infections like COVID and flu…Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.”  mRNA COVID-19 vaccines are effective in preventing severe illness and death from the disease, and mRNA vaccine technology has potential applications for other infectious diseases, as well as chronic diseases like cancer. The cancellation removes the bulk of U.S. federal funding for mRNA research, leaving questions about future progress by the U.S. in this area of vaccine technology.
August 15, 2025HHS reinstates the defunct Task Force on Safer Childhood Vaccines.
– The original Task Force on Safer Childhood Vaccines, a federal panel created by Congress in 1986 “to improve the safety, quality, and oversight of vaccines” was disbanded in 1998, but HHS announces that the group will be re-instated at NIH with participation from officials at FDA, CDC, and other government agencies. The goal of the reconstituted Task Force will be “the development, promotion, and refinement of childhood vaccines that result in fewer and less serious adverse reactions than those vaccines currently on the market, and improvements in vaccine development, production, distribution, and adverse reaction reporting” to help increase federal oversight and investigation of vaccine injuries.  The Task Force will come together to develop recommendations to be submitted to Congress within two years, with updates every two years after. Reinstatement of this panel has been a goal of anti-vaccine advocates for years, including the Children’s Health Defense, the anti-vaccine organization Secretary Kennedy founded, which supported a lawsuit earlier in 2025 against Kennedy that sought to require him to reconvene the Task Force.
August 27, 2025FDA approves COVID-19 vaccines for 2025-2026, while limiting scope of approval to certain ages and risk profiles.
– FDA approves updated COVID-19 vaccines for 2025-2026, but also limited the approval to persons 65 and older and those between 18 and 64 with a health condition that puts them at higher risk for severe disease. Previously, the FDA had approved the use of vaccines for all ages (over 6 months) regardless of risk profile.
September 9, 2025MAHA Commission releases strategy to address childhood chronic disease.
– A new MAHA Commission strategy document outlines actions the federal government is taking or plans to take to address childhood chronic disease in the U.S. These include “more than 120 initiatives” that together represent “the most ambitious national effort ever to confront childhood chronic disease,” and which outline a “blueprint for the entire government” to address chronic disease. Elements of the strategy include: changing federal science and research priorities, reforming dietary guidelines, changing nutrition and food regulations through reducing additives and ultra-processed foods, and improving effort to raise public awareness about chronic disease. The strategy highlights the risks of vaccine injuries, fluoride in drinking water, among many other areas.
September 18, 2025Secretary Kennedy renews the declaration of the national opioid crisis as a public health emergency.
– In a declaration on an HHS website, Secretary Kennedy renews the declaration of the opioid crisis as a national public health emergency (PHE).  The opioid crisis was initially declared a public health emergency in 2017; renewal is required every 90 days to continue the PHE.
September 19, 2025Secretary Kennedy announces that the FDA will launch a new review of mifepristone.
– Secretary Kennedy announced that the FDA will undergo a review of the current Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, due to new evidence including an April 2025 report from the Ethics and Public Policy Center (EPPC) which claims that mifepristone has a higher rate of adverse events than previously reported. This report has drawn criticism due to methodological flaws and lack of transparency regarding its data sources.
September 19, 2025ACIP makes several new recommendations related to MMRV and COVID-19 vaccines
– In its September 18-19 meeting, ACIP members vote on several new recommendations including to no longer recommend the combination MMRV (measles, mumps, rubella, and varicella) vaccine for children under the age of 4 and instead to recommend that children in this age group receive measles, mumps, and rubella (MMR) vaccine separately from the varicella vaccine (V). In addition, ACIP members vote to change what had been a universal COVID-19 vaccine recommendation (except for HHS’ recent change for healthy children and pregnant women) to “shared clinical decision-making”, including for those 65 and older, along with a recommendation for new language on risk-benefit for COVID-19 vaccinations. ACIP’s recommendations were adopted by CDC on October 6. While the separate MMR+V vaccines had been recommended as preferred by the CDC for many years, the combination MMRV provided an option for parents to reduce the number of injections their children receive. Now, insurers will no longer be required to cover this vaccine at no-cost. The new COVID-19 vaccine recommendations mean people of all age groups are now recommended to have an interaction with a health care provider (which could include a doctor, nurse, or pharmacist) to determine whether getting a COVID-19 vaccination is recommended for them. If that determination is made, insurers must cover the vaccine at no-cost, although it is possible that some consumers may face challenges in accessing providers in the first place or demonstrating that they have consulted with a medical provider seeking vaccination in some cases.    
September 22, 2025President Trump and Secretary Kennedy announce new actions to address autism spectrum disorder in the U.S.
– In a press conference and via an HHS press statement and Fact Sheet, President Trump and HHS Secretary announce several actions to address the issue of autism spectrum disorder (ASD) in the U.S. This includes FDA authorization for leucovorin, a treatment option for some children with autism, a regulatory change that will allow state Medicaid programs to newly cover leucovorin for the indication of ASD. President Trump and Secretary Kennedy also highlight what they say are risks of acetaminophen use during pregnancy and association with autism. The press release notes “HHS wants to encourage clinicians to exercise their best judgment in use of acetaminophen for fevers and pain in pregnancy by prescribing the lowest effective dose for the shortest duration when treatment is required.”  In his remarks, President Trump also implicated childhood vaccines as a potential risk factor for autism, though no new evidence was presented and that link has already been repeatedly and conclusively ruled out. In a subsequent press statement on September 22, HHS announced FDA was initiating a labeling change for leucovorin, and a safety label change for acetaminophen to include information about the “potential risks of acetaminophen so patients can make a more informed decision.” Public health groups and experts criticized the conclusions linking acetaminophen use in pregnancy and autism, and expressed doubts about leucovorin as a treatment for autism. President Trump’s remarks also precipitated a lawsuit filed on October 28 in Texas against the maker of Tylenol.
September 30, 2025FDA approves a new generic mifepristone product.
– The FDA approved Evita’s Solutions application for a generic version of mifepristone.   The approval included a reminder that the generic mifepristone is subject to the same  Risk Evaluation and Mitigation Strategy (REMS) as the brand-name.
September 30, 2025HHS awards $60 million in grants to support prevention of falls and related programs for older adults and those with disabilities.
– Secretary Kennedy announced 59 new grants totaling $60 million is being awarded to states, territories, tribes, and local organizations supporting older adults and Americans with disabilities, including programs for “preventing falls among seniors, managing chronic conditions…and funding dementia-capable programs.”
October 10, 2025Trump Administration fires thousands of HHS employees, including hundreds at CDC, during federal government shutdown.
– In the midst of a government shutdown and an ongoing federal funding impasse in Congress, the White House Office of Personnel and Management says over 4,000 federal workers are to be fired. At HHS, over a thousand workers are notified that they have lost their jobs, with most of those losses concentrated at CDC. Some of those job losses were reversed over the next few days, with HHS officials stating some notices were sent in error. Even so, as of October 14 it is estimated that about 600 CDC employees remain fired, including staff in areas such as injury prevention, health statistics, and Congressional relations. There is a question about whether such firings during a government shutdown are legal, and groups representing federal workers have filed lawsuits to halt these mass layoffs.
October 31, 2025FDA announces new restrictions on ingestible fluoride products for children.
– FDA announces new enforcement actions “to restrict the sale of unapproved ingestible fluoride products for children” and sends letters to health care professionals warning about the risks associated with these products. The actions come after FDA conducted a review and published a scientific evaluation of these products. In the announcement. FDA says it will be developing a “fluoride research agenda” and “the first national oral health strategy” for the U.S. in partnership with NIH and other HHS agencies.
November 10, 2025FDA announces a warning label change on hormone replacement therapy (HRT) products for addressing symptoms of menopause.
– In a press release, a fact sheet, and a live press event, FDA leaders announce that they will initiate the removal of broad “black box” warnings from HRT products for menopause. The FDA also announces approvals for two new drugs for menopausal symptoms. According to the FDA, women have been “under-utilizing approved therapies” since the “black box” warnings about risks associated with the drugs were placed on these products over 20 years ago. Labels will be rewritten with guidance saying that there are long-term health benefits if HRT is begun within 10 years of the onset of menopause.
November 19, 2025CDC changes language on its website to say a link between vaccines and autism cannot be ruled out.
– A CDC website providing information to the public on Autism and Vaccines, is changed to include language saying “studies have not ruled out the possibility that infant vaccines cause autism.” The new site also discusses the “state of the evidence” on common childhood vaccines and supposed links to autism. The new language is a reversal from previous CDC statements saying “vaccines do not cause autism,” and contradicts the long established scientific consensus that there is no link between vaccines and autism. The new CDC webpage language has been criticized by professional medical organizations such as the American Medical Association and the American Academy of Pediatrics, as well as autism organizations such as Autism Speaks and the Autism Science Foundation.
November 21, 2025CDC staff ordered to end all monkey research programs, potentially affecting development of prevention tools for HIV and other infectious diseases.
– According to reports, CDC staff are ordered to halt its monkey research program by the end of 2025. This program has helped develop HIV prevention tools such as pre-exposure prophylaxis (PrEP) and microbicides, as well supported prevention research for other infectious diseases.
November 28, 2025Internal FDA communication proposes stricter federal requirements for testing and approving vaccines.
– According to reports, the head of FDA’s Center for Biologics Evaluation and Research (CBER), which is responsible for regulating vaccines, issues an email to staff proposing new, stricter federal requirements for vaccine testing, evidence, and approval. The email states that in the future FDA will “demand pre-market randomized trials assessing clinical endpoints for most new products” and that FDA “will not be granting marketing authorization to vaccines in pregnant women” without this kind of evidence. Newly developed pneumonia, influenza, and COVID-19 vaccines are specifically mentioned as vaccines that would be subject to these new requirements. The rationale given for this policy change is a new analysis of vaccine safety data indicating “COVID-19 vaccines have killed American children,” though no evidence to support that statement is provided in the email.
December 5, 2025ACIP votes to end recommendation that all newborns receive hepatitis B vaccine dose at birth
On the second day of the Advisory Committee on Immunization Practices’ (ACIP) December 4-5 meeting, members vote to end a long-standing recommendation that all newborns in the U.S. receive a dose of hepatitis B vaccine. The committee now recommends parents of infants born to mothers who test negative for hepatitis B consult with their provider to help decide if and when their child should receive the first hepatitis B dose. ACIP continues to recommend that infants born to mothers who test positive for hepatitis B, or whose hepatitis B test status is unknown, receive the first hepatitis B vaccine dose at birth. A recommendation from ACIP becomes part of the official CDC immunization schedule once it is adopted by the CDC director.
December 30, 2025HHS ends certain requirements for state reporting of immunization data to the Centers for Medicare and Medicaid Services (CMS).
December 30 letter from the Centers for Medicare and Medicaid Services (CMS) informs state health officials that starting in 2026, states will no longer be required to report several measures related to immunization status to CMS. Specifically, CMS removes the following from its “Child and Adult Core Sets”: “Childhood Immunization Status”, “Immunizations for Adolescents”, “Prenatal Immunization Status: Under Age 21”; and “Prenatal Immunization Status: Age 21 and Older.” In addition, in its letter CMS informs state health officials it will “explore options to facilitate the development of new vaccine measures that capture information about whether parents and families were informed about vaccine choices, vaccine safety and side effects, and alternative vaccine schedules” and “how religious exemptions for vaccinations can be accounted for.” Data reported by states and included in the Child and Adult Core Sets are used by Medicaid and CHIP to monitor access to and quality of health care for their beneficiaries, so an absence of this data could make monitoring immunization coverage in this population more challenging.
January 5, 2026HHS announces changes to the federal childhood vaccination schedule that reduce the number of routinely recommended vaccines
Health and Human Services (HHS) issues a memo implementing major changes to the government’s recommended vaccination schedule for children. Under the new guidelines, there are vaccines for 11 diseases recommended for all children, down from 17 diseases a year ago. In addition to COVID-19 (which HHS stopped recommending for all children back in October 2025), the new schedule no longer recommends routine vaccinations for five other diseases: rotavirus, COVID-19, influenza, hepatitis A, hepatitis B, and meningococcal. These vaccines have been moved from routine recommendation to “shared clinical decision making,” a process that is “individually based and informed by a decision process between the health care provider and the patient or parent/guardian.”  The HPV vaccine remains recommended for routine vaccinations, though under the new guidelines HHS reduces the number of recommended doses of HPV drops from two or three (depending on age of initial vaccination) to one. Coverage for all of these immunizations should remain the same through public and private insurance mechanisms.
February 3, 2026BARDA opens solicitations for a $100 million prize program for development of novel antivirals targeting dengue, West Nile, and other viruses.
In a news release, HHS’ Biomedical Advanced Research and Development Authority (BARDA) announces it is opening solicitations for a share of a new $100 million SMART Antiviral prize intended to speed the development of “broad-spectrum, small-molecule antiviral therapies” targeting families of viruses that include dengue, Zika, West Nile, and Chikungunya. This first stage is designed to receive solicitations at the concept stage, with solicitations for further development stages anticipated in the future.
February 4, 2026Trump Administration instructs CDC to rescind $600 million in public health funds going to four Democratic-led states
According to reports, the Office of Management and Budget ordered CDC to cut $600 million in funding that had been earmarked for state and local public health programs in California, Colorado, Illinois, and Minnesota. Most of the funding cuts affect programs focused on HIV and STD prevention, are are to be terminated because they “do not reflect agency priorities” according to an HHS spokesperson. On February 11, affected states filed a lawsuit in federal court against these cuts, and on February 12 a federal judge issued a temporary restraining order blocking the cuts from taking effect.
February 10, 2026FDA refuses to review Moderna’s license application for its investigational mRNA-based influenza vaccine
Moderna announces it received a “Refusal to File” letter from FDA stating that the agency will not initiate a review of the company’s biological license application for its investigational mRNA-based seasonal influenza vaccine. According to FDA, the refusal is due to the company’s use of an inadequate comparison arm in its study. Moderna states the letter is “inconsistent with previous written communications” with FDA staff. On February 18, Moderna announced that FDA had reversed its decision, and will now review the application, following further discussions with the company.
February 18, 2026FDA to allow drug approvals with evidence from one clinical trial rather than two
In an opinion article published in the New England Journal of Medicine, FDA leaders announce a new FDA policy that will make the default requirement for FDA approvals to be results from one clinical trial instead of the prior requirement of two clinical trials.  The stated goal of the change is to accelerate the approval and availability of new medicines.
February 19, 2026CDC delays February ACIP meeting
HHS/CDC announces the ACIP meeting previously scheduled for February 25-27 will be postponed. The postponement occurs amid an ongoing federal lawsuit filed by the American Academy of Pediatrics (AAP) and other medical groups that argues the recent revisions made by HHS to the federal child immunization schedule were arbitrary and violated administrative procedures and seeks to have the ACIP panel appointed by HHS Secretary Kennedy removed and replaced and its decisions overturned. On February 26, CDC announced the ACIP meeting had been rescheduled for March 18-19. On March 16, 2025, the judge ruled that 13 of 15 ACIP member appointments did in fact violate administrative procedures and their appointments are stayed along with any ACIP votes since the appointments were made. As a result, the planned March 18-19 ACIP meeting has been canceled.
February 23, 2026FDA launches new framework for speeding development and approval of therapies for rare diseases
FDA announces draft guidance for drug developers that seek approval for targeted, individualized therapies. The new framework outlines new approaches to regulatory review and evidence requirements on the safety and efficacy for rare diseases, given that traditional randomized clinical trials may not be feasible for these conditions.
March 4, 2026HHS Postpones Third Straight Meeting of US Preventive Services Task Force (USPTF)
USPTF, which makes recommendations on preventive health care services, has not met since March of 2026. Five of the 16 USPTF members’ terms have ended as of January 1 and have not been replaced.  

Medicaid Postpartum Coverage Extension Tracker

Published: Mar 19, 2026

The Medicaid program finances about 4 in 10 births in the U.S. Federal law requires states to provide pregnancy-related Medicaid coverage through 60 days postpartum. After that period, some postpartum individuals may qualify for Medicaid through another pathway, but others may lose coverage, particularly in non-expansion states. To help improve maternal health and coverage stability and to help address racial disparities in maternal health, a provision in the American Rescue Plan Act of 2021 gave states a new option to extend Medicaid postpartum coverage to 12 months via a state plan amendment (SPA). This new option took effect on April 1, 2022 and was originally available for five years; however, the option was made permanent by the Consolidated Appropriations Act 2023. The Centers for Medicare and Medicaid Services (CMS) released guidance on December 7, 2021 on how states could implement this option.

States that sought to implement extended postpartum coverage prior to April 1, 2022 have done so through a section 1115 waiver or by using state funds. This page tracks state actions to implement extended Medicaid postpartum coverage, including states that have implemented a 12-month postpartum extension, states that are planning to implement a 12-month extension, states with pending legislation to seek federal approval through a SPA or 1115 waiver, and states that have proposed or received approval for a limited coverage extension.

Medicaid Postpartum Coverage Extensions: Approved and Pending State Action as of March 19, 2026

Postpartum Coverage Tracker Map (Choropleth map)

Medicaid Postpartum Coverage Extensions: Approved and Pending State Action as of March 19, 2026

>

What to Know About Medicare Coverage of Telehealth

Published: Mar 19, 2026

Editorial Note

This explainer was updated on March 19, 2026 to include the latest data about telehealth in Medicare.

Introduction

Use of telehealth, which includes a range of health care services delivered to patients by providers at a separate location, has grown rapidly in recent years, among both privately-insured patients and Medicare beneficiaries. Prior to the COVID-19 pandemic, telehealth utilization in traditional Medicare was very low, but it rose dramatically in 2020 following temporary measures put in place at the start of the COVID-19 public health emergency that greatly expanded the scope of Medicare coverage of telehealth. Since early 2021 telehealth use has declined steadily, but it remains higher than pre-pandemic levels, with considerable variation by level of income, disability, and urban versus rural location, among other factors.

Congress has repeatedly extended several pandemic-era flexibilities around Medicare coverage of telehealth, but with a few key exceptions (discussed below), most pandemic-era telehealth flexibilities remain temporary. This leaves them vulnerable if authorization lapses, such as during the government shutdown that began on October 1, 2025, when Medicare coverage of many telehealth services briefly lapsed before being retroactively reinstated on November 12, and creates uncertainty for both providers and beneficiaries. Many of Medicare’s telehealth flexibilities were recently granted a two-year extension under the Consolidated Appropriations Act of 2026 and will remain in effect through December 31, 2027, while a handful have been incorporated into the program on a permanent basis through prior legislation and through the annual physician fee schedule rulemaking process. There is bipartisan support for proposed legislation to permanently expand Medicare coverage of telehealth, and many health care providers are supportive of keeping these services accessible, but questions remain about the longer-term impact on patient care, Medicare spending, and program integrity.

This brief provides answers to key questions about the current scope of Medicare telehealth coverage, including both temporary and permanent changes adopted through legislation and regulation, and policy considerations that lie ahead.

Key Takeaways:

  • Congress has enacted legislation several times to extend Medicare’s expanded coverage of telehealth, which is currently due to expire in December 2027. Prior to the COVID-19 public health emergency, Medicare coverage of telehealth was limited to beneficiaries in rural areas and to certain types of providers, facilities, and services.
  • While use of telehealth in traditional Medicare has declined since the early months of the COVID-19 pandemic, use remains nearly two times higher than it was pre-pandemic. Use is higher among urban (vs. rural) beneficiaries, beneficiaries who are dually eligible for both Medicare and Medicaid (vs. beneficiaries who are not Medicaid eligible), and beneficiaries with disabilities or end-stage renal disease (vs. beneficiaries who qualify for Medicare based on age).
  • Medicare currently pays telehealth providers at different rates depending on the location of the beneficiary receiving the service. Medicare pays telehealth providers at a higher rate for telehealth services provided to beneficiaries located in their homes than for telehealth services provided to beneficiaries located in a separate clinical setting from the provider. When telehealth is provided to beneficiaries in clinical settings, Medicare also pays a separate fee for practice expenses to the facility where the beneficiary is located, which results in total Medicare payments that are generally higher relative to home-based telehealth despite the lower provider payment rate.
  • Coverage rules are different in Medicare Advantage, where plans have some flexibility to offer additional benefits, including telehealth benefits, not routinely covered by traditional Medicare (outside of the current temporary flexibilities).
  • Policymakers have considered legislation that would permanently expand Medicare coverage of telehealth, and are weighing the implications for Medicare spending and program integrity.

What is the Current Scope of Medicare Telehealth Coverage?

Prior to the declaration of the COVID-19 public health emergency, Medicare coverage of telehealth was largely restricted to beneficiaries in rural areas and to certain types of providers, facilities, and services. Beneficiaries were typically required to travel from their homes to an approved site, such as a clinic or doctor’s office, when receiving telehealth services. To make it easier and safer for beneficiaries to seek medical care during the pandemic, the Secretary of the Department of Health and Human Services (HHS) waived many of these restrictions in March 2020, enabling broader use of telehealth for all Medicare beneficiaries. While the pandemic-related expansion of telehealth coverage under Medicare was initially due to expire at the end of the COVID-19 public health emergency, Congress has extended these flexibilities several times, most recently through December 2027, and incorporated select provisions into the program on a permanent basis (Figure 1).

The following list summarizes key provisions related to coverage of telehealth in traditional Medicare under current law, both temporary and permanent, as well as limited changes made through the annual physician fee schedule rulemaking process. (See section below for a discussion of telehealth coverage by Medicare Advantage plans.)

Temporary Telehealth Provisions (Extended by Congress Through December 31, 2027)

  • Waiver of geographic and “originating site” requirements: Telehealth is currently available to Medicare beneficiaries in both urban and rural areas, and patients can receive telehealth services from any location, including their home as the “originating site.” Prior to the expansion, telehealth coverage in traditional Medicare was generally limited to rural areas, and patients were required to travel to an approved originating site, such as a clinic or doctor’s office, when receiving telehealth services. (Providers participating in select accountable care organizations (ACOs) are permitted to waive these requirements under the Bipartisan Budget Act of 2018, and may continue to provide telehealth services without geographic restrictions, and to beneficiaries in their homes, should the current temporary flexibilities expire.)
  • Expansion of covered telehealth services: Medicare currently offers coverage for an expanded set of telehealth services, including physical and occupational therapy, emergency consultations, and nursing facility care. Prior to the expansion, Medicare offered coverage for a more limited set of telehealth services, such as preventive health screenings, office visits, and psychotherapy. The Centers for Medicare & Medicaid Services (CMS) has the authority to expand the list of allowable telehealth services when there is a demonstrable clinical benefit and continues to evaluate select services for inclusion on this list. Beginning in 2026, CMS has taken steps to simplify the process of expanding telehealth coverage to new services, such as eliminating the distinction between “provisional” and “permanent” services. In past years, services were often added on a provisional basis before being considered for permanent inclusion.
  • Coverage of audio-only services: Medicare currently allows many telehealth services to be provided to patients via audio-only platforms, such as a telephone or a smartphone without video. Prior to the expansion, Medicare required all telehealth services to be provided via a two-way audio/video connection, such as an interactive audio-video system or a smartphone with video enabled.
  • Expansion of eligible “distant site” telehealth providers: Currently, any health care provider who is eligible to bill for Medicare-covered services can provide and bill for telehealth as a “distant site” telehealth provider and may conduct an initial telehealth visit whether or not they have treated the beneficiary previously. Additionally, federally qualified health centers (FQHCs) and rural health clinics (RHCs) are authorized to provide and bill for telehealth. Prior to the expansion, only physicians and certain other providers (e.g., physician assistants, clinical social workers, and clinical psychologists) were permitted to bill for telehealth services as the distant site provider and must have treated the beneficiary receiving those services within the last three years. FQHCs and RHCs were not authorized to serve as distant site providers but could serve as originating sites if located in a qualifying area.
  • Waiver of in-person visit requirement for behavioral health: Currently, Medicare beneficiaries receiving behavioral health services may opt to receive these services via telehealth with no in-person visit requirements. The Consolidated Appropriations Act of 2021 made numerous changes to Medicare coverage of behavioral telehealth (see below), including a provision that beneficiaries must have an in-person visit with their behavioral health provider no more than six months before their initial telehealth appointment and annually thereafter. Subsequent legislation has delayed this requirement, which is currently due to take effect in January 2028.
  • Use of telehealth for hospice recertification: Patient recertification for the Medicare hospice benefit can currently be conducted via telehealth, provided there is a two-way audio/video connection that allows for real-time interaction between the patient and hospice provider. Prior to the expansion, only in-person encounters could be used for the purposes of hospice recertification.

Permanent Telehealth Provisions:

  • Behavioral health: The Consolidated Appropriations Act of 2021 permanently removed geographic and originating site restrictions for any telehealth service used to diagnose, evaluate, or treat a mental health disorder. (These restrictions had already been lifted for treatment of substance use disorders and co-occurring mental health disorders in 2018.) While many provisions related to Medicare telehealth coverage are due to expire at the end of 2027, Medicare beneficiaries may continue to receive behavioral health services from their homes, in both urban and rural areas, and may do so via audio-only platforms if they are unable to access a video connection or do not consent to video use. Additionally, FQHCs and RHCs are permanently allowed to serve as “distant site” telehealth providers for behavioral health services.
  • Removal of frequency limitations: CMS recently finalized a provision in the 2026 Physician Fee Schedule Final Rule that permanently removes frequency limitations for subsequent inpatient visits, nursing facility visits, and critical care consultations provided via telehealth. This provision took effect on January 1, 2026. However, in the absence of further action by Congress, as of January 1, 2028 (when the current temporary flexibilities expire), implementation of this provision will be limited to the types of providers, services, and settings where telehealth was permitted before the current flexibilities were put in place.
  • Virtual instruction and direct supervision: The 2026 Physician Fee Schedule Final Rule also includes provisions permanently allowing direct supervision of many procedures by physicians and other supervising providers to be conducted virtually via two-way audio/video connections as well as permanently allowing teaching physicians to instruct residents virtually in all teaching settings when overseeing services provided via telehealth. These provisions took effect on January 1, 2026. However, as with other changes made through the physician fee schedule rulemaking process, implementation of these provisions will be limited in scope after January 1, 2028 should the current flexibilities expire.

What Share of Medicare Beneficiaries Use of Telehealth Services?

Telehealth use in traditional Medicare increased dramatically at the start of the COVID-19 public health emergency, with nearly half (46.7%) of all eligible beneficiaries receiving at least one telehealth service in the second quarter of 2020, compared to just 6.9% in the first quarter (Figure 2). While use has declined since that time, it remains nearly two times higher than pre-pandemic levels, with more than one in ten (12.5%) eligible beneficiaries receiving a telehealth service in the second quarter of 2025 (the most recent period for which data is available).

More than 1 in 10 Traditional Medicare Beneficiaries Used Telehealth in the First Half of 2025, a Decline from Early in the COVID-19 Pandemic but Higher Than Pre-Pandemic Levels (Line chart)

Use of telehealth services varies by geography, race and ethnicity, reason for Medicare eligibility, and dual enrollment in Medicare and Medicaid (Figure 3).

Telehealth Use is Higher Among Urban Beneficiaries, Duals, and Beneficiaries with Disabilities or End-Stage Renal Disease, with Some Variation by Race and Ethnicity (Split Bars)

Reason for Medicare eligibility: Rates of telehealth use in 2024 were higher among beneficiaries who qualify for Medicare based on having end-stage renal disease (ESRD) (37%) or a long-term disability (36%), relative to those who qualify based on age (23%). This may be due in part to higher overall rates of service use among people with ESRD and disabilities (whether in-person or via telehealth) but may also reflect a preference for telehealth among these populations, or a greater ease of accessing care via telehealth relative to in-person care. Beneficiaries under age 65 who qualify for Medicare based on having long-term disabilities are more likely than older beneficiaries to report having three or more limitations in activities of daily living, and may be more likely to benefit from the increased flexibility of receiving health care services from their home via telehealth.

Dual-eligible individuals: Rates of telehealth use in 2024 were higher among beneficiaries dually eligible for both Medicare and Medicaid compared to Medicare beneficiaries who were not Medicaid eligible (35% vs. 23%). Dual-eligible individuals are four times more likely than other Medicare beneficiaries to live on incomes of less than $20,000. Prior studies have found that having lower income or living in a socioeconomically deprived neighborhood is associated with higher rates of telehealth use, suggesting that telehealth may have the potential to improve health care access for beneficiaries with limited access to in-person services.

Geography: Rates of telehealth use in 2024 were higher among beneficiaries living in urban areas than those in rural areas (26% vs. 19%), which may be due in part to disparities in access to broadband and other communication technologies. Beneficiaries in rural or underserved areas may lack the infrastructure to support reliable video telehealth visits or the means to afford internet access, which may further impede access to telehealth if coverage of audio-only services is reduced or eliminated.

Race and ethnicity: Rates of telehealth use in 2024 were highest among Asian and Pacific Islander (30%) and Hispanic (29%) beneficiaries, and somewhat lower among Black (26%), American Indian or Alaska Native (24%), and non-Hispanic White beneficiaries (24%). Given that beneficiaries of color are more likely than non-Hispanic White beneficiaries to report difficulty accessing needed health services, telehealth use may help to improve access to care for certain groups.

How Does Medicare Pay Providers for Telehealth Services?

As of January 2024, Medicare pays for telehealth services based on the location of the beneficiary. Medicare pays providers at a higher rate for telehealth services provided to beneficiaries who are located in their homes and a lower rate for telehealth services provided to beneficiaries who are located in a separate clinical setting (i.e., originating site) (with that lower rate being the same regardless of whether the clinical setting is a doctor’s office or a facility, such as a rural health clinic). According to CMS, the higher rate paid by Medicare for telehealth services provided to beneficiaries in their homes better reflects the practice expenses of providers in mental health and certain other specialties who provide a significant share of their services via telehealth, but also maintain an office for in-person services, an arrangement that became common after the telehealth expansion allowed for greater numbers of beneficiaries to access telehealth from home.

However, when beneficiaries receive telehealth services in clinical settings, such as a rural health clinic, Medicare makes a separate payment to the originating site (the “facility fee”) to reimburse for the cost of practice expenses, and the telehealth service provider is reimbursed at a lower rate that solely reflects the cost of the service itself. This results in total Medicare payments that are generally higher when beneficiaries receive telehealth in clinical settings despite the lower payment to the telehealth service provider.

In contrast, Medicare pays for most in-person services based on the location of the provider. For services furnished in a non-facility setting, such as a doctor’s office, providers are reimbursed at a higher rate that reflects the cost of some practice expenses as well as reimbursement for the service itself (equivalent to the rate paid for telehealth services provided to beneficiaries in their homes). For services furnished in a facility setting, such as a hospital outpatient department, providers are solely reimbursed for the service provided (equivalent to the rate paid for telehealth services provided to beneficiaries in clinical settings), and practice expenses are reimbursed directly to the facility as a separate facility fee. As in the case of clinic-based telehealth, the addition of the facility fee means that total Medicare payments are generally higher for facility- than non-facility-based services, though the provider portion of these payments is smaller.

How Do Medicare Advantage Plans Cover Telehealth?

Medicare Advantage plans are required to cover all Part A and Part B benefits covered under traditional Medicare, and have some flexibility to offer additional benefits as well, including telehealth benefits not routinely covered by traditional Medicare (outside of the current telehealth expansion), such as telehealth services provided to enrollees in their own homes, services provided outside of rural areas, and services provided through audio-only platforms.

Since 2020, Medicare Advantage plans have been permitted to include the costs associated with select telehealth services in their basic Medicare Part A and B benefit package, and may continue to do so after December 2027 regardless of the status of the temporary telehealth expansions in traditional Medicare. Telehealth services may be included in a plan’s basic benefits package if they meet certain requirements, such as coverage under Medicare Part B when the same service is provided in person. When these requirements are not met, plans may continue to offer supplemental telehealth benefits via remote access technologies and/or telemonitoring services, but must cover the cost of these benefits using rebates or supplemental premiums.

What Has Been Proposed to Expand Medicare Coverage of Telehealth?

While Congress has enacted legislation to extend temporary telehealth flexibilities in Medicare since 2023, there has been little movement on bills that would permanently extend these flexibilities. For example, the CONNECT for Health Act of 2025, introduced by Senator Schatz, would permanently implement several key pandemic-era telehealth flexibilities, such as the removal of geographic and originating site requirements and the broad expansion of providers eligible to offer telehealth, but has not been scheduled for a vote.

Trump administration officials, including CMS Administrator Dr. Mehmet Oz, have voiced support for the use of telehealth and other health technologies to increase access to health care services and promote treatment of chronic disease. The upcoming Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model from the Center for Medicare & Medicaid Innovation (CMMI) will test the impact of new payment options designed to incentivize the use of technologies such as telehealth platforms, wearable devices, and health care apps for prevention and management of certain chronic conditions, though these payment options will be temporary and limited to the performance period of the model.

Finally, at the state level, certain states have taken action to develop multi-state licensure compacts, which have allowed for additional flexibility related to licensure in participating states. Medicare providers are generally required to be licensed in any state where they are practicing, and this requirement extends to telehealth. In most cases, a distant site telehealth provider must be licensed in the state where the beneficiary receiving services is located when the telehealth visit takes place, but multi-state licensure compacts can extend these permissions to a wider area. These compacts are formed when states agree upon a uniform standard of care and enact state laws which allow qualified providers to practice across state lines while maintaining a single license, to maintain multiple licenses, or which expedite the process of gaining additional licensure across member states. These compacts may be continued beyond December 2027, though other restrictions may limit their use if the current flexibilities are allowed to expire.

What Are the Implications of Telehealth for Program Integrity?

As policymakers weigh whether to permanently implement current flexibilities around Medicare coverage of telehealth, several questions have been raised about the impact of telehealth services on patient care quality and program spending, as well as the potential for fraud and overuse.

Since the current flexibilities were introduced, state and federal agencies have filed several lawsuits regarding the submission of fraudulent claims by telehealth companies to Medicare and other insurers. However, investigations by the HHS Office of the Inspector General (OIG) into provider billing patterns during the first year of the COVID-19 pandemic found that just 0.2% of providers who billed for a telehealth service during the period engaged in excessive billing patterns that posed a high risk to the Medicare program, and clinicians generally complied with Medicare requirements when providing Evaluation and Management services through telehealth, suggesting little evidence of widespread misuse to date. MedPAC has recommended that CMS take certain precautions going forward, such as applying additional scrutiny to “outlier” clinicians who deliver more telehealth services than others and requiring in-person visits before high-cost tests and medical equipment are paid for.

What are the Implications of Telehealth for Medicare Spending?

The impact of expanded telehealth coverage on Medicare spending is difficult to assess, as it depends on several factors. Some telehealth services may replace in-person care, as in the case of behavioral health visits, but easier access to telehealth may also lead to an overall increase in use of services and higher costs. Prior research has found modest increases in clinical encounters and spending per person among Medicare beneficiaries in geographic areas and health systems with higher rates of telehealth use. At the same time, there is evidence to suggest that beneficiaries with greater access to telehealth services may have fewer emergency department visits and improved adherence to certain medications. Additional research could help policymakers and other interested parties assess the degree to which any increases in Medicare spending as a result of expanded telehealth coverage are offset by improvements in quality of care or decreases in other costs, such as spending on preventable hospital admissions and other types of acute care services.

The Congressional Budget Office (CBO) scored the extension of current telehealth flexibilities through December 2027 under the Consolidated Appropriations Act of 2026 as costing $3.8 billion from 2026 to 2028. CBO has not yet scored the cost of recent legislative proposals, such as the CONNECT for Health Act of 2025, that would implement these flexibilities on a permanent basis.

Poll Finding

Cost Concerns and Coverage Changes: A Follow-Up Survey of ACA Marketplace Enrollees

Published: Mar 19, 2026

Findings

About the Survey

At the end of 2025, despite a government shutdown over the policy, the enhanced premium tax credits expired, decreasing financial assistance for subsidized Marketplace enrollees and contributing to significant increases in the Affordable Care Act (ACA) Marketplace costs for most enrollees overall. Amid the debates leading up to the expiration, KFF conducted a probability-based survey of 1,350 adults covered by ACA Marketplace plans in late 2025 to better understand their worries about potential cost increases for their health coverage. Now—without the enhanced tax credits in place—KFF re-interviewed 1,117 individuals (more than 80% of the original sample) to learn how they are navigating these changes to the ACA Marketplace. 

This report is based on all 2025 Marketplace enrollees who took the follow-up survey, including returning Marketplace enrollees1, those who have left the Marketplace entirely for another type of coverage, and those who are now uninsured.

Summary of Findings

Half of those who have re-enrolled in ACA Marketplace coverage say their health care costs are “a lot higher” this year. Following the expiration of the enhanced premium tax credits and an open enrollment period that left many Affordable Care Act (ACA) Marketplace enrollees feeling “worried” and “angry,” most of those who have re-enrolled in Marketplace coverage now report paying more for coverage. A large majority (80%) of returning Marketplace enrollees say their 2026 plan’s premiums, deductibles, or coinsurance and co-pays are higher than last year, including half (51%) who say they are “a lot higher.”

ACA Marketplace enrollees worry about affording their monthly premiums, as well as out-of-pocket expenses such as emergency care or routine medical visits. With many returning Marketplace enrollees reporting higher costs this year, majorities express worry about affording both routine and unexpected medical care. Three in four (73%) returning Marketplace enrollees say they are “very worried” or “somewhat worried” about being able to afford costs for emergency care or hospitalizations while about half are worried about affording costs for routine medical visits (49%) or prescription drugs (45%). Worries are even greater among those with lower incomes and those with chronic health conditions. In addition, one in six (17%) returning Marketplace enrollees say they are not confident they will be able to afford their monthly health insurance premium for the entirety of 2026. This is even as a quarter of those who switched plans say they downgraded their plan’s metal tier (e.g. from a Silver plan to a Bronze plan) in 2026, which generally have lower premiums but typically have higher out-of-pocket costs.

Health care costs are straining household budgets. Among 2025 Marketplace enrollees who have re-enrolled in Marketplace coverage, many report that their health care costs are putting pressure on household budgets. A majority (55%) of returning Marketplace enrollees say they are (or will be) cutting back spending on food or basic household items in order to afford the costs of coverage and care. The impact is even harder for returning enrollees with chronic health conditions, with 62% saying they are, or will be, cutting back on food and other household items in order to help them afford their health care costs.

Bar chart showing health care cost concerns among 2025 ACA Marketplace enrollees who still have Marketplace coverage.

Some previous ACA Marketplace enrollees are now uninsured or have changed to a different Marketplace plan, citing costs as the major reason for that decision. One in ten (9%) 2025 Marketplace enrollees say they are now currently uninsured and three in ten (28%) say they switched to a different Marketplace plan. When asked the reasoning behind their change, a larger share say costs were the driver rather than changes to their health care needs. A 34-year-old man living in Texas put it this way, “The prices are simply too high. $800/month for the absolute cheapest plan for two people. Our income is $120k, so we don’t qualify for subsidies in Texas. I don’t think we could afford our mortgage if I had to pay for health insurance.”

Health care costs may be a deciding factor for ACA Marketplace enrollees in the 2026 midterm elections. With health care costs front and center for 2025 Marketplace enrollees, many who are registered to vote say that the cost of health care will have a major impact on their decision to vote (48%) and which party’s candidate they will support (49%) in the midterm elections. The issue currently resonates more with Democrats, who are more than twice as likely as Republicans to say health costs will play a major impact on their decision to vote in the 2026 midterms (67% vs. 27%) and on which candidate they decide to vote for (70% vs. 30%).

Where Are They Now? Coverage Changes Among 2025 Marketplace Enrollees

The Follow-Up Survey of ACA Marketplace Enrollees finds most (69%) 2025 enrollees say they have re-enrolled in Marketplace coverage for 2026, including four in ten (39%) who say they are enrolled in the same plan they had in 2025 and nearly three in ten (28%) who have switched to a different Marketplace plan. This is largely consistent with the 2025 survey findings in which a third said they would be “very likely” to look for a different Marketplace plan if their premiums doubled.

Additionally, about three in ten 2025 Marketplace enrollees now say they no longer have Marketplace coverage, including 22% who transitioned to a different source of coverage, such as through an employer, by becoming eligible for programs like Medicare or Medicaid, or say they have now purchased a non-Marketplace health insurance plan (some of which may provide less comprehensive coverage and have fewer consumer protections than Marketplace plans). One in ten (9%) 2025 Marketplace enrollees say they are currently uninsured. A large amount of churn on and off the Marketplace is normal as ACA Marketplace coverage is often a temporary source of coverage between jobs, and because income, age, and other circumstantial changes can make people newly eligible for other public programs such as Medicaid or Medicare.

Bar chart showing health insurance coverage type among 2025 Marketplace enrollees.

Notably, half (49%) of younger 2025 Marketplace enrollees between the ages of 18 and 29 report having left the Marketplace entirely, including 14% who say they are currently uninsured. In contrast, smaller shares of older 2025 Marketplace enrollees—ages 50 and up—say they are currently uninsured (7%). Additionally, younger 2025 enrollees are also more likely than their older counterparts to say they have left the Marketplace for another source of coverage—which would be expected with life changes such as starting a new job, getting married, or experiencing a change in income. Significant shares of younger adults having left the Marketplace in 2026 is consistent with previous KFF policy analysis on the expiration of the enhanced tax credits, which attributes part of this year’s increases to insurers anticipating healthier (e.g. younger) adults exiting the Marketplace, creating an enrollee base that is more expensive on average.

Stacked bar chart showing health insurance coverage type by age among 2025 Marketplace enrollees.

Among those who still have a Marketplace plan, one in six (17%) returning enrollees say they are “not too” or “not at all” confident they will be able to afford their insurance premiums for all of 2026. This may put them at risk of losing their Marketplace coverage at some point this year.

Stacked bar chart showing confidence in affording monthly health insurance premiums for the entire year among 2025 Marketplace enrollees who still have Marketplace coverage.

Additionally, 4% of returning Marketplace enrollees say they have yet to pay their first premium for 2026. Notably, returning enrollees who receive tax credits to help pay for their coverage are generally provided with a 3-month grace period for nonpayment of premiums, meaning most may have until the end of March to pay any premiums that are due before facing the retroactive termination of their health insurance coverage.

Costs Are a Major Reason Why Enrollees Switched to a Different Marketplace Plan or Dropped Coverage

Almost four in ten (37%) 2025 enrollees are either uninsured or switched to a different Marketplace plan. When asked the reasoning behind their change, a larger share say costs were the driver rather than changes to their health care needs. Eight in ten say they made a change to their coverage because it was too expensive, including seven in ten (71%) who say this was a “major reason” and one in ten (9%) who said it was a “minor reason.” Just over a third (36%) say changing health needs were a major or minor reason why they changed plans or dropped their Marketplace coverage.

Stacked bar chart showing reasons 2025 Marketplace enrollees made changes to their health insurance coverage. Results reported among 2025 Marketplace enrollees who either switched to a different Marketplace plan or are currently uninsured.

Many 2025 enrollees who switched Marketplace plans this year say their previous plans’ premiums increased dramatically when selecting coverage for 2026. Additional reasons for changing plans include their old plans no longer being available and general dissatisfaction with their previous plan.

In Their Own Words: What is the main reason you switched to a different Marketplace plan this year?

“The cost of the same plan I had in 2025 tripled in price to $360/month. So I went with a different plan that cost less. But even it was higher than the plan I had in 2025.” – 62-year-old man, Wisconsin

“The price went from 2k to 3500 for a household of 4 people.” – 37-year-old man, Florida

“Income exceeded the subsidy limit, forcing us to pay the full cost, so we switched down to a bronze from a gold plan. Even doing that our premiums are 3 times what they were in 2025, with lower plan features and a higher deductible.” – 56-year-old man, Texas

“Cost. By switching to Bronze, I would receive a tax credit that covered my plan. If I had stayed on my Silver plan, I would’ve had to pay out-of-pocket, which my budget does not allow for.” – 26-year-old woman, Montana

“In 2025 I had the elite bronze plan. The monthly premium cost of the plan I had in 2025 went up, the PCP and prescription copays went up, and the deductible went up almost $4000. To keep my out of pocket expenses the same and given my prior history…I had to drop to the everyday bronze with a much larger deductible and just hope that I continue not to actually need anything unexpected.” – 55-year-old man, South Carolina

Health Care Costs Weigh Heavily on the Now Uninsured

Among the 9% of 2025 enrollees who say they are currently uninsured, survey responses indicate that the cost of health care played a major role in their decision to drop coverage, and many from this group report worrying about affording medical care.

In Their Own Words: What is the main reason you are currently without health insurance coverage?

“The end of ACA subsidies caused a huge increase in premiums, the cost of which I could not afford.” – 63-year-old man, California

“Even though I make some income (too much for subsidies, even last year), the increase is so high even for those without subsidies. I simply cannot afford to pay $1,200 a month for insurance. It used to be high premiums meant low deductibles and copays, but not anymore. This is ridiculous. $1,200 for a healthy person, and an $8,000 deductible. Really?” – 56-year-old woman, Illinois

“[I am] self-employed and [there are] no cheap health plans.”– 24-year-old man, Florida

“Without the subsidy, I cannot afford the premium payments.”– 54-year-old man, Texas

“The prices are simply too high. $800/month for the absolute cheapest plan for two people. Our income is $120k, so we don’t qualify for subsidies in Texas. I don’t think we could afford our mortgage if I had to pay for health insurance. $800/month is 8 self pay doctors visits a month. If I have a catastrophic health event it makes more sense for me to just declare bankruptcy than it would be to be delinquent on other payments.” – 34-year-old man, Texas

Many 2025 enrollees who are now uninsured cite fears about accessing and affording care in the case of unexpected medical emergencies. Some who have significant health issues say their main worry about not having health insurance is being unable to afford necessary medications and treatment.

In Their Own Words: What is your main worry, if any, about not currently having health insurance?

“Not managing ongoing health issues and pre-existing conditions.” – 48-year-old woman, Colorado

“Everything. Can’t afford insurance can’t afford health care without insurance so basically just hoping and praying I don’t get sick or have any major issues pop up.” – 38-year-old man, Alabama

“We are 59 and 61 yrs old. We need healthcare. And now we will either avoid seeing a dror go bankrupt.” – 59-year-old woman, Virginia

“I’m in my ‘50s and have some health concerns that I won’t be able to address this year.” – 55-year-old man, Idaho

Health Care Costs Contribute to Affordability Worries and Challenges Among Returning Marketplace Enrollees

Following the expiration of the ACA enhanced premium tax credits in December 2025, a large majority (80%) of returning Marketplace enrollees say their health care costs are higher this year compared to 2025. This includes half (51%) of returning enrollees who say their health care costs—whether it be their premiums, deductibles, and/or their coinsurance and co-pays—are “a lot higher” compared to last year.

About six in ten (63%) returning Marketplace enrollees say their monthly health insurance premium is higher than 2025, including 40% who say it is “a lot higher.” In addition, nearly half say their deductibles are higher (45%, including 24% who say they’re “a lot higher”), and one-third say their coinsurance and co-pays are higher compared to last year (36%, including 18% “a lot higher”).

Increases in insurance plan cost-sharing are pronounced among those who say they switched their Marketplace plan this year. Over half (54%) of returning enrollees who switched plans say their deductibles are higher this year compared to last year (including 34% who say “a lot higher”), and an additional four in ten (42%) say their coinsurance and co-pays are higher (25% “a lot higher”). This likely reflects the fact that some enrollees switched to lower tier Bronze plans which may mitigate some of the increase in premiums but typically have higher out-of-pocket costs. Overall, a quarter (26%) of plan switchers say they downgraded their metal plan (e.g. from a Silver plan to a Bronze plan) in 2026.

Stacked bar chart showing share of adults who say their premiums, deductibles, or coinsurance/copays are a lot higher, somewhat higher, lower, or about the same as last year. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage.

While most 2025 Marketplace enrollees say they still have Marketplace coverage in 2026, having insurance does not insulate them from worrying about the costs of accessing care. About three in four (73%) returning Marketplace enrollees say they are “very worried” or “somewhat worried” about being able to afford costs for emergency care or hospitalizations while about half are worried about affording costs for routine medical visits (49%) or prescription drugs (45%).

Stacked bar chart showing share of adults who say they are worried about affording health care costs like emergency care, routine medical care, and prescription drugs. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage.

At least seven in ten returning Marketplace enrollees across income groups say they are worried about being able to afford costs for emergency care or hospitalization. However, those with lower incomes are more likely than their higher-income counterparts to worry about being able to afford prescription drugs. Those with chronic conditions are more likely than those without such conditions to worry about affording emergency care, routine care, and the cost of prescription medications.

Split bar chart showing shares of adults who say they are "very" or "somewhat worried" about affording health care costs like emergency care, routine medical care, and prescription drugs. Results shown by total, household income, and chronic health condition status. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage.

Rising health care costs can place considerable pressure on household budgets and create additional financial strain. Just over four in ten (44%) returning Marketplace enrollees say their health care costs have made it harder to afford other expenses, including over a third (37%) who say it has made it more difficult to afford food and groceries and about three in ten who say it has made it more difficult for them to afford their monthly utilities (32%), their rent or mortgage (30%), or gasoline or other transportation costs (30%)

About half of returning Marketplace enrollees with lower household incomes and those with chronic health conditions report that their health care costs are placing financial strain on other expenses.

Split bar chart showing share of adults who say their health care costs made it more difficult to afford food and groceries, monthly utilities, rent/mortgage, gasoline and transport, or any of the above. Results shown by total, household income, and chronic health condition status. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage.

A majority (55%) of returning Marketplace enrollees say they have already, or are planning to, cut back spending on food or basic household items in order to cover any health care related costs. Around four in ten (43%) say they have already or are planning to find an extra job or work more hours to cover health expenses, while about two in ten are skipping or delaying paying other bills (23%) or taking out loans or increasing their credit card debt (20%). Notably, while one in five returning enrollees say they are already looking for another job or trying to find more hours, an increase in income could help them afford their premium or deductible payments, but it could also mean they become eligible for less financial assistance.

Returning Marketplace enrollees with chronic conditions are among the most likely to report taking steps to cover their costs, with about six in ten (62%) saying they have or plan to cut back on spending, half (52%) saying they have or plan to work more, a third (33%) saying they will skip or delay paying bills, and a quarter (26%) saying they will take out a loan or increase their credit card debt.

Stacked bar chart showing share of adults who are already or plan on cutting back on spending, finding an extra job, skipping bills, or taking out a loan in order to cover any costs related to health care. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage.

In Their Own Words: What changes or actions have you taken or think you may take in order to afford your health care costs this year?

“Attempt to pay off loans to free up more monthly money, budget groceries more tightly, put hospital debt on a payment plan.” – 24-year-old woman, Kentucky

“Cut back on food expenses, choose cheaper & fewer dining out experience, watch heat & AC usage even more.” – 54-year-old woman, California

“Attempt to use as little health care as possible. Make sure our doctors and hospitals are covered by the insurance. Talk with our doctors to verify that ordered treatments and/or drugs are really necessary. Discuss with providers/pharmacies to see if self-pay may be cheaper than using insurance in particular cases.” – 56-year-old man, Texas

“Shopping for cheaper groceries, not buying clothes, avoiding getting sick, not being as social.” – 63-year-old woman, California

“Pare back expenses as much as possible.” – 39-year-old man, Iowa

“Limit going to the doctor. I can’t afford the medications prescribed so I try to find over the counter substitutions.” – 54-year-old woman, Texas

“My grocery budget and fun budget are smaller so we can afford the premium.” – 38-year-old woman, Colorado

“I may have to get part-time employment. I may have to get a job after being retired.” – 60-year-old woman, Florida

Open Enrollment Process Left Many Marketplace Enrollees Worried and Angry

Following the expiration of the enhanced premium tax credits for ACA Marketplace coverage, many 2025 Marketplace enrollees say they felt worried or angry as they went through the process of evaluating their health insurance options for 2026. Nearly two-thirds (63%) of 2025 Marketplace enrollees say they felt “worried” during the process of looking for coverage while about half (52%) say they felt “angry.” Nearly half (46%) say the process made them feel “confused,” while nearly four in ten (37%) say they were “satisfied” during the process of looking for insurance coverage for this year.

Bar chart showing adults who say they felt "worried", "angry", "confused", or "satisfied" about the process of looking at health insurance coverage options for 2026. Results reported among 2025 Marketplace enrollees.

Reactions to the Expiration of Enhanced Premium Tax Credits

In a recent KFF Health Tracking poll, a majority of the public overall said Congress did the wrong thing by letting the enhanced premium tax credits for people who buy their insurance on the ACA Marketplace expire. Unsurprisingly, 2025 Marketplace enrollees share this sentiment, with eight in ten (78%) saying that Congress did the wrong thing by letting the credits expire, while two in ten say Congress did the right thing.

Majorities of 2025 Marketplace enrollees across partisanship agree that Congress did the wrong thing, including nearly all Democrats (94%), eight in ten independents, and six in ten Republicans (58%). Even among Trump’s base—Republicans and Republican-leaning independents who support the MAGA (Make America Great Again) movement—a majority (54%) say that Congress did the wrong thing by letting the credits expire.

Mirrored bar chart showing the share of the public who say Congress did the right thing or the wrong thing by letting the enhanced tax credits expire. Shown among total 2025 Marketplace enrollees and by party identification. Results reported among 2025 Marketplace enrollees.

When asked how they feel about the expiration of the enhanced premium tax credits, many 2025 Marketplace enrollees express anger, frustration, and disappointment. While some are fine with the expiration or note that it has not impacted them, many are upset at the rise in their own insurance costs and the government’s failure to extend the credits.

In Their Own Words: How do you feel about Congress letting the enhanced premium tax credits for the Affordable Care Act (ACA) expire?

“Angry. They get affordable good coverage even when they aren’t doing ANYTHING. We struggle to pay for health insurance. And they gut the ACA without offering any alternative.” – 60-year-old independent woman, California

“I am okay with it. It was not going to be able to sustain itself so it needed to happen.” – 48-year-old Republican woman, Florida

“Evil on the part of republicans. Absolutely ineffectual on the part of democrats.” – 33-year-old Democratic man, Washington

“It’s a disgrace that families are being put in this position to chose between health insurance and all other household needs.” – 42-year-old Democratic woman, Pennsylvania

“It could hurt some people but the impact to me is minimal.” – 56-year-old independent man, California

“There should have been a gradual decrease versus a sudden cut off or more communication so that people could prepare as needed and advocate where possible.” – 44-year-old Democratic woman, California

“I feel as if it’s unfair to those who make too much to be able to receive Medicaid. We are getting penalized for making more money than poverty level.” – 26-year-old independent woman, Florida

“It needs to expire and pharmaceutical companies need to have a cap on prices. They should not be able to charge so much. Also, put a cap on insurance company premiums too.” – 47-year-old independent woman, Georgia

“It has had a major financial impact on my already financially stressed household as I am fully disabled in a wheelchair and unable to work and also unable to receive disability or social security.” – 58-year-old Republican woman, Texas

Among all 2025 Marketplace enrollees, about six in ten (62%) place the most blame on either President Trump (32%) or Republicans in Congress (30%), while a smaller share (14%) say Congressional Democrats deserve the most blame. Two in ten think Congress did the right thing by letting the tax credits expire.

While very few Democratic 2025 Marketplace enrollees blame their own party (3%) for the expiration of the enhanced tax credits, three in ten Republicans, including two in ten MAGA-supporting Republicans, place the most blame on either President Trump or Republicans in Congress.

Stacked bar chart showing percent who say either Democrats in Congress, Republicans in Congress, or President Trump, deserves most of the blame for the enhanced tax credits expiring. Results shown by total 2025 Marketplace enrollees and by party identification. Results reported among 2025 Marketplace enrollees.

Potential Political Impacts of Higher Health Care Costs Among Marketplace Enrollees

When it comes to increases in their own health care costs, returning Marketplace enrollees blame lawmakers alongside health insurance and pharmaceutical companies.

Among the eight in ten returning Marketplace enrollees who say their premiums or cost-sharing are higher this year, seven in ten say health insurance companies deserve “a lot” of blame for the increase. Although the public perceive health insurance companies as a major source of blame for their cost increases, lack of action by Congress in extending the tax credits is attributed as the main cause of increases in premiums and other costs according to KFF policy analysis. Majorities of returning Marketplace enrollees also say Republicans in Congress (54%), President Trump (53%), and pharmaceutical companies (52%) deserve “a lot” of blame for the increase in their health care costs. A third (34%) of returning Marketplace enrollees who report having higher health care costs say Democrats in Congress deserve “a lot” of blame. Fewer place “a lot” of blame on hospitals (30%), doctors (12%), or employers (8%). Notably, around half or more of those who report that their premiums, deductibles, or coinsurance and co-pays are higher this year than last year place at least some blame on each of the groups asked about.

Stacked bar chart showing adults who say each of the following deserve "a lot of blame" or "some blame" for the increase in their health care costs. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage and said their health care costs are higher this year compared to last year.

Across partisanship, at least two-thirds of returning Marketplace enrollees whose health care costs (including premiums, deductibles, or coinsurance and co-pays) are higher now than last year say health insurance companies deserve “a lot” of blame, and around half or more place “a lot” of blame for their increased costs on pharmaceutical companies. However, when it comes to lawmakers, there is a predictable partisan division. Among returning Marketplace enrollees with higher health care costs than last year eight in ten or more Democratic enrollees place “a lot” of blame on President Trump (83%) and on Congressional Republicans (80%) for their increased costs. In contrast, six in ten returning Republican enrollees who now have higher health care costs place “a lot” of blame on Democrats in Congress, as do MAGA supporting Republican enrollees.

Split bar chart showing share of returning Marketplace enrollees who say each of the following deserves "a lot of blame" for the increase in their health care costs. Results shown among 2025 Marketplace enrollees who still have Marketplace coverage and by party identification. Results reported among 2025 Marketplace enrollees who still have Marketplace coverage and said their health care costs are higher this year compared to last year.

Health care costs may impact enrollees’ decisions at the ballot box this November, and in some congressional districts, the number of Marketplace enrollees could be enough to swing close elections. Three-quarters of 2025 Marketplace enrollees who are registered to vote say the cost of health care will have a “major impact” or “minor impact” on their decision to vote (73%) and which party’s candidate they will support (74%) in the midterm elections. Majorities of voters across partisanship say health care costs will impact their voting decisions, however Democrats are more than twice as likely as Republicans to say it will have a major impact on their decision of whether to vote (67% vs. 27%) and on which party’s candidate they will support (70% vs. 30%). At least four in ten independent voters say that health care costs will have a major impact on their decision to vote (47%) and who they decide to vote for (44%).

Stacked bar chart showing percent who say the cost of health care will have a "major impact", "minor impact" or "no impact" on their decision to vote and which candidate's party they would support in the 2026 midterm elections. Results reported among 2025 Marketplace enrollees who are registered to vote.

Beyond being motivated to vote, some enrollees have taken actions to discuss their rising health care costs with friends and family, online, or by directly contacting an elected official. Three-quarters (76%) of 2025 Marketplace enrollees have discussed the cost of health insurance with friends or family, including similar shares across partisanship. However, few report taking further action, including one in seven (14%) who have contacted an elected official by phone, mail, internet, or in person to discuss the cost of health insurance and one in nine (12%) who have posted on social media about the cost of health insurance.

Democrats are more likely than Republicans to say they have contacted an elected official (17% vs. 10%) or have posted on social media about the cost of their coverage (16% vs. 7%).

Split bar chart showing share of adults who say they have discussed the cost of health insurance with family, contacted any elected officials to discuss the cost of health insurance, or posted on social media about the cost of health insurance. Results reported among 2025 Marketplace enrollees.

Methodology

This KFF Follow-Up Survey of Marketplace Enrollees was designed and analyzed by public opinion researchers at KFF. The survey was conducted February 12- March 2, 2026, online and by telephone among a nationally representative sample of 1,117 U.S. adults who had Marketplace insurance in 2025 in English (n=1,079) and in Spanish (n=38). The sample is entirely derived from people who completed the KFF Marketplace Survey in 2025 (n=1,350). 

The original sample was recruited using two probably-based panels, the SSRS Opinion Panel and the IPSOS Knowledge Panel. The SSRS Opinion Panel is a nationally representative probability-based panel where panel members are recruited randomly in one of two ways: (a) Through invitations mailed to respondents randomly sampled from an Address-Based Sample (ABS) provided by Marketing Systems Groups (MSG) through the U.S. Postal Service’s Computerized Delivery Sequence (CDS); (b) from a dual-frame random digit dial (RDD) sample provided by MSG. For the online panel component, invitations were sent to panel members by email followed by up to three reminder emails. The IPSOS Knowledge Panel is a nationally representative probability-based panel where panel members are recruited randomly through invitations mailed to respondents randomly sampled from an Address-Based Sample (ABS) through the U.S. Postal Service’s Computerized Delivery Sequence (CDS). The follow-up sample included 842 individuals from SSRS Opinion Panel and 264 reached through the Ipsos Knowledge Panel. 

An additional 11 adults who were previously recruited to complete a KFF survey in 2024-2025 and were reached via their prepaid cell phone number. A small group of these individuals reported that they had Marketplace coverage in 2025.  Among this prepaid cell phone component, 4 were interviewed by phone and 7 were invited to the web survey via short message service (SMS). 

Respondents in the prepaid cell phone sample who were interviewed by phone received a $15 incentive via a check received by mail. Respondents in the prepaid cell phone sample reached via SMS received a $10 electronic gift card incentive. SSRS Opinion Panel respondents received a $5 electronic gift card incentive (some harder-to-reach groups received a $10 electronic gift card). Ipsos operates an incentive program that includes raffles and sweepstakes with both cash rewards and other prizes to be won. An additional incentive is usually provided for longer surveys. In order to ensure data quality, cases were removed if they failed two or more quality checks: (1) attention check questions in the online version of the questionnaire, (2) had over 30% item non-response, or (3) had a length less than one quarter of the mean length by mode. Based on this criterion, there were 2 cases removed. 

The combined recontacted cell phone and panel samples were weighted to match the sample’s demographics to the national U.S. adult population aged 18-64 who are currently covered by direct-purchase insurance using data from the Census Bureau’s 2025 Current Population Survey (CPS). The demographic variables included in weighting are Sex by Age, Education, Sex by Education, Age by Education, Race/Ethnicity, Census Region, Number of Adults in Household, Home Tenure (Own/Rent), and residence in a Medicaid Expansion state. Additionally, the weights account for differences in the probability of selection for each sample type (prepaid cell phone, IPSOS Knowledge Panel, and SSRS Opinion Panel). This includes adjustments for ownership of a prepaid cellphone, the design of the panel-recruitment procedure (IPSOS Knowledge Panel and SSRS Opinion Panel), and propensity to complete the recontact interview. 

The margin of sampling error including the design effect for the full sample is plus or minus 3.8 percentage points. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available on request. Sampling error is only one of many potential sources of error and there may be other unmeasured error in this or any other public opinion poll. KFF public opinion and survey research is a charter member of the Transparency Initiative of the American Association for Public Opinion Research.

GroupN (unweighted)M.O.S.E.
Total 2025 Marketplace enrollees1,117± 4 percentage points
   
Returning Marketplace enrollees794± 4 percentage points
Returning enrollees with the same plan as 2025437± 6 percentage points
Returning enrollees who switched to different Marketplace plan345± 7 percentage points
   
Party ID  
Democrats525± 6 percentage points
Independents133± 11 percentage points
Republicans408± 6 percentage points
   
MAGA Republicans258± 8 percentage points

Endnotes

  1. This survey includes 794 returning Marketplace enrollees: respondents who say they are currently enrolled in the Marketplace, irrespective of whether they effectuated their enrollment. Some returning Marketplace enrollees may retroactively lose their health coverage for 2026 if they do not make their first premium payment. ↩︎
News Release

KFF Follow-Up Survey of Marketplace Enrollees: Following End of Enhanced Credits, Half of Marketplace Enrollees Now Say Costs Are a Lot Higher, Most Expect to Cut Back on Basic Household Expenses to Afford Coverage

One in 10 Dropped Their Marketplace Coverage and Are Now Uninsured and Three in 10 Switched ACA Plans, Most Citing High Costs

Published: Mar 19, 2026

Following the expiration of the enhanced premium tax credits for people with Affordable Care Act (ACA) Marketplace plans, a new KFF follow-up survey of the same Marketplace enrollees KFF surveyed in 2025 finds half (51%) of returning enrollees say their health care costs are “a lot higher” this year compared to last year, including four in 10 who specifically say their premiums are “a lot higher.” In all, a large majority (80%) of these enrollees say their health care costs, which can include premiums, deductibles, co-pays, or coinsurance, are higher.

This new survey, which was fielded about a month after open enrollment ended in most states and before the grace period to make payments ends for many enrollees, re-interviewed Marketplace enrollees who shared their expectations for their coverage decisions late last year. It also finds that nearly one in six (17%) returning ACA Marketplace enrollees say they are not confident they will be able to afford their premiums this year. For those who kept the same Marketplace plans, the expiration of the ACA’s enhanced premium tax credits in 2025 is estimated to have increased annual premium payments by more than two-fold on average this year.

Responding to Rising Health Costs
Among those who re-enrolled in an ACA Marketplace plan, a majority (55%) say they have cut or plan to cut spending on food or other basic household expenses to afford their health care costs. The impact is even greater for those with chronic health conditions, more than six in 10 (62%) of whom say they are, or will be, cutting back on food and other basics.

Marketplace enrollees are also concerned about their ability to pay for both routine and unexpected medical expenses. About three in four (73%) returning Marketplace enrollees say they are “very worried” or “somewhat worried” about being able to afford costs for emergency care or hospitalizations while about half are worried about affording costs for routine medical visits (49%) or prescription drugs (45%).

“The impacts on Marketplace enrollees we see in this follow-up survey will likely get worse as people struggle to make payments and the grace period many have expires,” KFF President and CEO Drew Altman said.

For some, rising costs have already forced them to make tough choices. About one in 10 (9%) Marketplace enrollees dropped their ACA coverage and are now uninsured and another nearly three in 10 (28%) changed Marketplace plans. When asked why they decided to drop or change their coverage, most cited costs.

A 63-year-old man in California describes why he is uninsured now:
“The end of ACA subsidies caused a huge increase in premiums, the cost of which I could not afford.”

A 56-year-old man in Texas explains why he switched to a different Marketplace plan:
“Income exceeded the subsidy limit, forcing us to pay the full cost, so we switched down to a bronze from a gold plan. Even doing that our premiums are 3 times what they were in 2025, with lower plan features and a higher deductible.”

In all, seven in 10 (69%) of those who had ACA Marketplace coverage in 2025 have re-enrolled in a plan through the Marketplace, while others became eligible for different types of health insurance coverage either through an employer (5%) or through Medicare (4%) or Medicaid (7%). A small share (5%) purchased health plans outside of the ACA Marketplace, which typically provide less comprehensive coverage and have fewer consumer protections than Marketplace plans. Even in years with few policy changes, shifts across Marketplace plans or to other types of coverage are normal and often follow changes in employment, income, age, and other life circumstances.

Looking Ahead to the Midterms
Among returning Marketplace enrollees who saw higher health costs, seven in 10 (70%) blame health insurance companies “a lot” for their increased costs and at least half place “a lot” of blame on congressional Republicans (54%), President Trump (53%), or pharmaceutical companies (52%). While majorities of partisans place “a lot” of blame on lawmakers from the opposite party, independents with Marketplace coverage are more likely to say Congressional Republicans (56%) and President Trump (58%) deserve “a lot” of blame than Congressional Democrats (28%).

Three-quarters of those who had Marketplace coverage in 2025 and are registered to vote say health care costs will affect their decision to vote (73%) and which party’s candidate they will support (74%). Democrats are more than twice as likely as Republicans to say it will have a major impact on their decision to vote (67% vs. 27%) and which candidate they may support (70% vs. 30%). Among independent voters, nearly half say the issue will have a major impact on their decision to vote (47%) and which candidate they will support (44%).

Designed and analyzed by public opinion researchers at KFF, this survey, which builds on a 2025 survey of ACA Marketplace enrollees, re-interviewed more than 80% of the original sample to learn how they are navigating changes to the ACA Marketplace. The survey was conducted February 12-March 2, 2026, online and by telephone, in English and in Spanish, among a nationally representative sample of 1,117 U.S. adults who had ACA Marketplace coverage in 2025 and completed the initial KFF survey. The margin of sampling error is plus or minus four percentage points for the full sample. For results based on other subgroups, the margin of sampling error may be higher.

KFF QUIZ

How Well Do You Understand Your Health Insurance?

Health insurance is often complicated, but understanding the basics helps you make better decisions about your coverage and care. This 10-question quiz touches on some terms you may encounter. Test your knowledge and pick up some useful insights along the way.

Question 1 of 10
Which statement best describes a health insurance premium?
Question 2 of 10
Which of the following is the best definition of the term “annual health insurance deductible”?
Question 3 of 10
Which statement describes the difference between a copayment and coinsurance?
Question 4 of 10
Your health insurance plan has a $1,000 deductible for hospital care and a $250 per-day copayment once the deductible is met. You are hospitalized for 4 days, and the hospital charges negotiated with the insurance company (the “allowed amount”) total $6,000. How much would you be responsible for paying?
Question 5 of 10
Which statement describes a Health Savings Account (HSA)?
Question 6 of 10
When you receive care from an out-of-network medical professional or facility, what costs might you be responsible for? (“Out of network” refers to a doctor, hospital, or facility that does not have a contract with your health insurance plan.)
Question 7 of 10
Under federal “surprise billing” protections, patients are generally shielded from higher out-of-network charges when they receive:
Question 8 of 10
What does it mean when a health care professional says that a test, procedure, or medication requires “prior authorization” in order for insurance to cover it?
Question 9 of 10
Which of the following best describes a prescription drug “formulary”?
Question 10 of 10
Which of the following are required to publicly post prices for health care services?

Global COVID-19 Tracker

Published: Mar 17, 2026

Editorial Note: The Policy Actions tracker will no longer be updated as the data source has ceased tracking government responses to COVID-19. For more information, please visit the Oxford Covid-19 Government Response Tracker.

Cases and Deaths

This tracker provides the cumulative number of confirmed COVID-19 cases and deaths, as well as the rate of daily COVID-19 cases and deaths by country, income, region, and globally. It will be updated weekly, as new data are released. As of March 7, 2023, all data on COVID-19 cases and deaths are drawn from the World Health Organization’s (WHO) Coronavirus (COVID-19) Dashboard. Prior to March 7, 2023, this tracker relied on data provided by the Johns Hopkins University (JHU) Coronavirus Resource Center’s COVID-19 Map, which ended on March 10, 2023. Please see the Methods tab for more detailed information on data sources and notes. To prevent slow load times, the tracker only contains data from the last 200 days. However, the full data set can be downloaded from our GitHub page. While the tracker provides the most recent data available, there is a two-week lag in the data reporting.

Note: The data in this tool were corrected on March 18, 2024, to clarify that they represent new cases and deaths over a full week rather than the average per day over a seven-day period.

Policy Actions

This tracker contains information on policy measures currently in place to address the COVID-19 pandemic. Policy categories currently being tracked include social distancing & closure measures, economic measures, and health systems measures. Policies are tracked at the country-, income-, and region-level. Please see the Methods tab for more detailed information on data sources and notes.

Social Distancing and Closure Measures

As countries continue to implement policies to prevent the transmission of SARS-CoV-2, the virus that causes COVID-19, these tables and charts show which social distancing and closure measures are currently in place by country.

Global COVID-19 Policy Actions

Economic Measures

The COVID-19 pandemic has placed an unprecedented strain on country economies. These tables and charts show which economic-related measures, namely income support and debt relief, are currently in place by country.

Global COVID-19 Policy Actions

Health Systems Measures

The COVID-19 pandemic continues to strain and disrupt global health systems. These tables and charts show which health systems measures are currently in place by country.

Global COVID-19 Policy Actions

Methods

Cases and Deaths

SOURCES

As of March 7, 2023, all data on COVID-19 cases and deaths are drawn from the World Health Organization’s (WHO) Coronavirus (COVID-19) Dashboard. Prior to March 7, 2023, this tracker relied on data provided by the Johns Hopkins University (JHU) Coronavirus Resource Center’s COVID-19 Map, which ends on March 10, 2023. Population data are obtained from the United Nations World Population Prospects using 2021 total population estimates. Income-level classifications are obtained from the latest World Bank Country and Lending Groups. Regional classifications are obtained from the World Health Organization.

Policy Actions

NOTES

Policy actions data include the measure that was in place for each indicator at the country-level as of the end of 2022. Policy actions data will no longer be updated as the data source has ceased tracking government responses to COVID-19. For more information, please visit the Oxford Covid-19 Government Response Tracker.

Social Distancing and Closure Measures

Under ‘Stay At Home Requirements’, exceptions for leaving the house may include anything from being able to leave for daily exercise, grocery shopping, and essential trips, to only being allowed to leave once a week, or one person may leave at a time, etc. Under ‘Workplace Closing’, partial closing includes instances in which a country recommends closing the workplace (or working from home); businesses are open but with significant COVID-19-related operational adjustments; or when workplaces require closing for only some, but not all, sectors or categories of workers. Under ‘School Closing’, partial closing includes instances in which a country has recommended school closures; all schools are open but with significant COVID-19-related operational adjustments; or some schools, but not all, are closed; full closing includes schools that are in session but operating virtually. Under ‘Restrictions On Gatherings’, partial restrictions include restrictions on gatherings of more than 10 people; full restrictions include restrictions on gatherings of 10 people or less. Under ‘International Travel Controls’, partial restrictions include screening and quarantine requirements for those entering the country. Values for ‘Cancel Public Events’ were not recodified.

Economic Measures

Under ‘Income Support’, narrow support includes instances in which a country’s government is replacing less than 50% of lost salary (or if a flat sum, it is less than 50% median salary); broad support includes instances in which a country’s government is replacing 50% or more of lost salary (or if a flat sum, it is greater than 50% median salary). Under ‘Debt/Contract Relief’, narrow support includes instances in which a country’s government is providing narrow relief, such as relief specific to one kind of contract.

Health Systems Measures

Under ‘Vaccine Eligibility’, partial availability includes availability for some or all of the following groups: key workers, non-elderly clinically vulnerable groups, and elderly groups, or for select broad groups/ages. Under ‘Facial Coverings’, recommend/partial requirement includes instances in which a country’s government recommends wearing facial coverings, requires facial coverings in some situations, and requires facial coverings when social distancing is not possible. 

SOURCES

Data on and descriptions of government measures related to COVID-19 provided by the Oxford Covid-19 Government Response Tracker (OxCGRT). For more detailed information on their data collection and methodology, please see their codebook and interpretation guide.

Key Global Health Positions and Officials in the U.S. Government

Published: Mar 17, 2026

This tracker is updated periodically and currently reflects major positions known to be filled or likely to be retained thus far in the second Trump administration (other key roles will be added as filled). Some of the officials noted in this tracker may be on administrative leave and not performing the duties of their roles under direction from the Trump administration.

PositionOfficial
WHITE HOUSE/EXECUTIVE OFFICE OF THE PRESIDENT
National Security Advisor/Assistant to the President for National Security Affairs, National Security Council (NSC)Marco Rubio
Director, Office of National AIDS Policy (ONAP)Vacant
Director, Office of Management and Budget (OMB)Russ Vought
U.S. Trade Representative, Office of the United States Trade Representative (USTR)Jamieson Greer
Director, Office of Science and Technology Policy (OSTP)Michael Kratsios
Director, Office of Pandemic Preparedness and Response Policy (OPPR)Vacant
DEPARTMENT OF STATE
Secretary of StateMarco Rubio
Permanent U.S. Representative to the United Nations, U.S. Mission to the United NationsMike Waltz
Senior Official, Under Secretary for Foreign Assistance, Humanitarian Affairs and Religious FreedomJeremy Lewin
Senior Bureau Official and Acting Global AIDS Coordinator, Bureau of Global Health Security and DiplomacyJeffrey Graham
Principal Deputy Assistant Secretary for Global Health Security and Diplomacy; Deputy Assistant Secretary for PEPFAR and Health Programs, Bureau of Global Health Security and DiplomacyRebecca Bunnell
Senior Advisor for Global Health Security and Diplomacy, Bureau of Global Health Security and DiplomacyBrad Smith
Assistant Secretary, Bureau of Democracy, Human Rights, and LaborRiley Barnes
Assistant Secretary, Bureau of Population, Refugees, and MigrationAndrew Veprek
Senior Bureau Official, Bureau of International Organization AffairsMcCoy Pitt
Assistant Secretary of State for Oceans and International Environmental and Scientific Affairs (OES)John Thompson
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
SecretaryRobert F. Kennedy Jr. 
Director, Office of Global Affairs (OGA)Bethany Kozma
Assistant Secretary for HealthBrian Christine
Surgeon GeneralCasey Means (Designate)
Principal Deputy Assistant Secretary for Preparedness and Response, Office of the Assistant Secretary for Preparedness and Response (ASPR)John Knox
Director, Center for the Biomedical Advanced Research and Development Authority (BARDA), ASPRGary Disbrow
HHS/CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
DirectorJay Bhattacharya
Director, Office of Readiness and ResponseHenry Walke
Director, Washington OfficeVacant
Director, Global Health Center (GHC)Paige Alexandra Armstrong
Director, Division of Global Health Protection, GHCBenjamin Park
Director, Division of Global HIV and TB, GHCHank Tomlinson
Director, Global Immunization Division, GHCJohn Vertefeuille
Director, Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)Simon Agolory
Director, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD)Vivien Dugan
HHS/NATIONAL INSTITUTES OF HEALTH (NIH)
DirectorJay Bhattacharya
Director, National Institute of Allergy and Infectious Diseases (NIAID)Jeffrey Taubenberger
Director, Office of Global Research, NIAIDJoyelle Dominique
Director, Division of AIDS, NIAIDRobert Eisinger
Director, Division of Microbiology and Infectious Diseases (DMID), NIAIDDavid Spiro
Director, Vaccine Research Center, NIAIDTed Pierson
Director, Office of AIDS Research (OAR); NIH Associate Director for AIDS ResearchGeri Donenberg
Director, Fogarty International Center (FIC); NIH Associate Director for International ResearchPeter Kilmarx
Director, Center for Global Health, Office of the Director, National Cancer InstituteSatish Gopal
Director, Office of Global Health, Office of the Director, National Institute of Child Health and Human DevelopmentVesna Kutlesic
Director, Center for Global Mental Health Research, National Institute of Mental HealthLeonardo Cubillos
HHS/FOOD & DRUG ADMINISTRATION (FDA)
CommissionerMarty Makary
Deputy Commissioner for Policy, Legislation, and International AffairsGrace Graham
Associate Commissioner for Global Policy and StrategyMark Abdoo
HHS/HEALTH RESOURCES AND SERVICES ADMINISTRATION (HRSA)
AdministratorThomas Engels
Associate Administrator, Bureau of HIV/AIDSHeather Hauck
Director, Office of Global Health, Office of Special Health InitiativesMelissa Ryan Kemburu
DEPARTMENT OF DEFENSE (DoD)
SecretaryPete Hegseth
Assistant Secretary of Defense for Health Affairs, Personnel and Readiness (P&R)Keith Bass
Commander, Naval Medical Research Command (NMRC)Eric Welsh
Director, DoD HIV/AIDS Prevention Program (DHAPP)Brad Hale
Commander, Walter Reed Army Institute of Research (WRAIR)Brianna Perata
Director, U.S. Military HIV Research Program (MHRP)Julie Ake
Chief, Armed Forces Health Surveillance Division (AFHSD)Richard Langton
Chief, Global Emerging Infections Surveillance (GEIS), AFHSDBrett Swierczewski
OTHER AGENCIES AND DEPARTMENTS
Peace Corps*: DirectorRichard Swarttz
Council of the Inspectors General on Integrity and Efficiency*: Chair, Pandemic Response Accountability CommitteeWilliam Kirk
Council of the Inspectors General on Integrity and Efficiency*: Executive Director, Pandemic Response Accountability CommitteeKenneth Dieffenbach
Department of Agriculture (USDA): SecretaryBrooke Rollins
Environmental Protection Agency (EPA)*: Assistant Administrator for International and Tribal AffairsUsha-Maria Turner
Department of Homeland Security (DHS): Chief Medical OfficerSean Conley
Notes: Acting officials in italics. Officials who the White House has signaled it intends to nominate or who are formally awaiting Senate confirmation are noted as “Designate.” tbd means to be determined. As of March 16, 2026. Also see NIH/FIC, Global Health Initiatives at NIH, available at: https://www.fic.nih.gov/Global/Global-Health-NIH/Pages/institute-center-ics-global-health.aspx.